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ABSTRACT 
ABSTRACT 
The potential use of human fetal pancreas as an alternative source for 
transplantable beta-cells to treating type 1 diabetes mellitus depends on its immune 
privilege as well as high capacity to proliferate and differentiate. This notion has been 
substantiated by a recent study showing a reduced immunogenicity of first-trimester 
human fetal pancreatic tissue. Meanwhile, we have successfully isolated, characterized 
and cultured a population ofpancreatic progenitor cells (PPCs) derived from human fetal 
pancreas that is amenable to growth and differentiation into insulin-producing islet-like 
cell clusters (ICCs). Despite this, the immunogenicity of these PPCs and ICCs has yet to 
be characterized. We thus hypothesize that the PPCs and ICCs derived from first-trimester 
possess lower immunogenicity than that derived from second-trimester of human fetal 
pancreas; we tested this hypothesis by characterizing and comparing the immune 
properties of these cells. 
In order to achieve this, we first investigated the expression profile of selected 
immune-related genes by real-time PCR. Expression of the major histocompatibility 
complex class I (MHC-I) molecules upon stimulation of interferon-gamma (IFN-y) was 
further examined by flow cytometry. Results showed positive gene expression of several 
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selected immune-related genes including MHC molecules, complement components (C3), 
apoptotic markers (TNFSF10), chemokine ligands (CCL19), innate molecules (B7H4). 
Both co-stimulatory molecule, CD80 and CD86, were found to be negative in both PPCs 
and ICCs. Upon stimulation of IFN-y, MHC-I expression on PPCs was upregulated in a 
dose-dependent manner. Comparison of these immunological markers in PPCs from the 
first and second trimesters was also undertaken. A differential gene expression of MHC-I 
was observed in PPCs from 9 to 14 weeks of gestation, with an enhanced expression from 
the second trimester. Expression of the pro-inflammatory genes was significantly elevated 
in PPCs from the second trimester, indicating an immuno-privilege of PPCs from the first 
trimester. We also confirmed a higher inducibility of MHC-I and MHC-II expression in 
PPCs from the second-trimester by IFN-y. 
Seondly, we investigated the alloreactivity of the progenitors in vitro by mixed 
lymphocyte reaction (MLR) and the proliferation ofhuman lymphocytes were determined 
by BrdU incorporation. Results revealed a significant higher stimulation of lymphocytes 
in MLR of PPCs from the second trimester. A higher production of IFN-y was also 
observed in Phytohemagglutinin (PHA-P) stimulated MLR with second trimester. Lastly, 
we further investigated the in vivo xenoreactivity by transplantation of ICCs into a mouse 
II 
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model of diabetes. Although both first- and second-trimester ICC grafts failed to 
normalize blood glucose in the diabetic mice, immunohistochemistry analysis of 
grafted-kidney revealed a significant increase in lymphocyte infiltration on 
second-trimester islet grafts, implicating a reduced immunogenicity in the ICCs of first 
over second trimester. 
Taken all these data together, we conclude that PPCs of first-trimester has an 
immune privilege over second-trimester derived from human fetal pancreas. The present 
study provides not only insights into the immunological properties of PPCs and ICCs but 
also perspective into the use of first-trimester PPCs as an alternative source for 
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CHAPTER 1 INTRODUCTION 
l.lThe pancreas 
1.1.1 Structure of pancreas 
The pancreas is an organ composed of two structurally distinct but functionally 
integrated parts, i.e. endocrine and exocrine glands. Embryologically, they are 
derived from an outgrowth of primitive gut tube of definitive endoderm. The major 
functions of the endocrine and exocrine glands are to produce islet cell hormones (e.g. 
insulin and glucagon) and acinar cell digestive enzymes, along with ductal cell 
sodium bicarbonate, to maintain nutrient homeostasis and assimilation, respectively. 
Structurally, the pancreas is a flat and elongated organ, which is more softly and less 
compactly arranged than the other organs. The pancreas is divided into three parts, 
namely the head, body and tail; the head of pancreas is embedded in the curvature of 
the first loop of the duodenum while the tail region is tucked into the hilum of the 
spleen (Figure 1.1). 
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The exocrine pancreas, consisting of pancreatic acinar cells and duct cells, is 
structurally analogous to a bunch of grapes in which the pyramidal-shaped acinar 
cells are packed into lobules and exocytose pancreatic enzymes into the blind-ended 
lumen of the acinus (Figure 1.2b & c). Exocrine secretions of digestive enzymes from 
acinar cells and sodium bicarbonate from ductal epithelial cells flow into intercalated 
ducts, larger intralobular ducts and major extrabobular duct, and finally drain to the 
main collecting duct that joins the common bile duct before entering into the 
duodenum (Figure 1.2a). (See review by Leung & Ip, 2006) 
Embedded within these exocrine structures are small clusters of cells called Islets of 
Langerhans or pancreatic islets that make up the endocrine portion of pancreas 
(Figure 1.2d). Despite their small porportion in the pancreas (1-2% of total mass) 
compared with the endocrine pancreas (>80%), pancreatic islets are capable of 
producing a number of physiologically important peptide hormones including insulin, 
glucagon, somatostatin, pancreatic polypeptides, and ghrelin for the regulation of 
nutrient, notably glucose homeostasis. (See review by Kulkarni, 2004) 
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Figure 1.2 The microscopic view of pancreas, pancreatic duct, acinar and islet of 
Langerhan. 
[Extractedfrom: Nabeel Bardeesy & Ronald A. DePinho. Pancreatic cancer biology and 
genetics. Nature Reviews Cancer 2，897-909. 2002] 
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1.1.2 Structure and function of exocrine pancreas 
As mentioned, the pancreatic exocrine gland, constituting over 80% ofthe total mass 
of the whole pancreas, is responsible for the production and secretion of digestive 
enzymes and an alkaline pancreatic juice. Such exocrine pancreatic secretions are 
fmely regulated by two major hormones, secretin and cholecystokinin (CCK), which 
are released from the gut endocrine cells, i.e. D cells and K cells, respectively, in 
response to food stimuli. The pancreatic acinar cells are highly polarized cells, with a 
large basolateral membrane located at the acinar periphery and the apical membrane 
facing the acinar lumen. The acinar cells are capable of synthesizing and secreting 
over 10 different proteases or hydrolytic enzymes; they include to name, but a few, 
a-amylase, lipase, protease, ribonuclease, and deoxyribonuclease, all ofwhich are the 
major digestive enzymes responsible for our daily food stuffs. 
The secretion by the exocrine pancreas is modulated by neural and hormonal 
signaling pathways in the form of diverse neurocrines, paracrines and endocrines 
from the gastrointestinal system (Chey & Chang, 2001). For example, the neurocrine 
acetylcholine (ACh), the endocrine cholecystokinin (CCK) and secretin as well as the 
paracrine vasoactive intestinal polypeptide (VIP) and recently proposed angiotensin 
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II (Ang II) are physiologically important in the regulation of exocrine function 
(Leung & Ip, 2006). Among these regulators, CCK, one of these enteric endocrine 
hormones, plays an important role in governing the secretory function of exocrine 
pancreas. CCK is synthesized and released from the duodenal I cells under the 
stimulation of partially digested proteins and fats which are emptied from the 
stomach. Once released into the blood stream, CCK binds to the Gotq 
G-proteins-linked CCKe receptor located on the cell membrane of pancreatic acinar 
cells, thus leading to the exocytosis of secretory granules via mediation of the 
phospholipase C (PLC)/Ca^^ signal transduction pathway (Wasle & Edwardson, 
2002). On the other hand, the actions of VIP and secretin are mediated via their 
respective membrane-bound receptors and they activate GoCs G-proteins that finally 
lead to the polarized secretion of the digestive enzymes or exocytosis into the acinar 
lumen (Wasle & Edwardson, 2002). Interestingly, the vasoactive peptide, Ang II, has 
been recently proposed to play a role in regulating digestive enzyme secretions such 
• as a-amylase and lipase from the pancreatic acinar cells (Tsang et al. 2004) 
The ductal cells represent the minority of exocrine pancreas, comprsing only 10% of 
number of cells and 5% of total mass of the human pancreas (Githens, 1988); 
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however, are indispensable for the normal functioning of enzymes and the integrity of 
the duodenal mucosa. As such, they produce sodium bicarbonate (HCO3')-rich 
alkaline fluid that provides optimal pH for pancreatic digestive enzymes as well as 
neutralizing gastric chyme which is emptied into the highly pH-sensitive duodenum. 
While secretin is the primary stimulus ofHCO3" secretion by ductal epithelium, CCK 
is able to potentiate secretin-mediated HCO3' release. In addition, somatostain is 
released from the endocrine D-cells in response to gastric chyme (pH <3.5) entering 
the duodenum and thus inhibit various gastrointestinal secretions (Bayliss & Starling, 
1902). 
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1.1.3 Structure and function of endocrine pancreas 
1.1.3.1 Pancreatic islet and islet cells 
As discussed, the endocrine pancreas is composed of islets of Langerhans or 
pancreatic islets, and their secretory products are physiologically critical for 
controlling glucose homeostasis. The islets are spherical in shape accounting only 
for 1-2% by volume of the total pancreatic mass. Each islet is richly supplied with 
blood vasculature, and the hormones that islet cells secrete enter these blood 
vessels directly. There are five major cell types which constitute the pancreatic 
islet, namely the alpha cells (a-cells), beta cells (p-cells), delta cells (5-cells), PP 
cells (also known as F-cells) and, to some extent, the epsilon cells (s-cells); these 
islet cells are responsible for the synthesis of glucagon, insulin, somatostatin, 
pancreatic polypeptide, and ghrelin, respectively (Kulkarni, 2004). Among the five 
cell types, P_cells are predominant, consisting of about 80% of the total population 
of islet cells. Such cell type is so orderly arranged in the islets that P-cells are 
‘ located in the centre closely surrounded by a - and 5-cells. Blood flows from the 
centre of the islet to the periphery in such a way that the a - and 5-cells are 
exposed to high concentrations of insulin, thus finely governing the release of 
glucagon and somatostatin in an autocrine manner. The distribution of these four 
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types of cells are uneven throughout the whole pancreas in which p_ and 6-cells 
are distributed throughout the whole pancreas, while a-cells are located 
exclusively in the tail, body and superior part of the head of the pancreas; on the 
other hand, PP cells are present in the middle and inferior parts ofhead ofpancreas 
(Wolfe-Coote & Du Toit, 1987). 
Glucagon, a catabolic hormone, is exclusively produced by a-cells of which its 
major physiological action is to increase the plasma glucose levels by stimulating 
the synthesis ofhepatic glucose via gluconeogenesis. The secretion of glucagon is 
activated by hypoglycaemic condition, high plasma levels of amino acids and 
epinephrine, as well as vagal activation. In addition, somatostatin inhibits glucagon 
release in a paracrine fashion. Generally speaking, glucagon is counteractive to 
insulin in terms oftheir physiological regulation on glucose homeostasis. 
• On the other hand, the function of p-cells is basically to synthesize and release 
insulin, an anabolic peptide hormone, in response to changes in plasma levels of 
major nutrients, particularly glucose, amino acids and fatty acids. The principal 
physiological action of insulin is to suppress levels of glucose via its uptake by 
10 
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peripheral tissues such as adipose and skeletal as well as decreasing hepatic 
glucose production. Pre(pro)insulin, the precursor of insulin, is cleaved into 
(pro)insulin within the endoplasmic reticulum. The (pro)insulin consists of an 
amino-terminal p_chain, a carboxy-terminal chain, and a connecting peptide 
between these two chains called the C-peptide. The conversion of a mature insulin 
from (pro)insulin requires the removal of this C-peptide by the cleavage action o f a 
specific endopeptidase known as prohormone convertase, which allows the 
exposure of the end of the insulin chain, thus rendering its interaction to insulin 
receptors (Steiner, 1997). The release of insulin is under regulation of numerous 
factors and they will be discussed in the following Sections. 
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1.1.3.2 Glucose-stimulated insulin secretion from islets 
As mentioned in section 1.1.3.1，the release of insulin by p-cells is under the 
influence of changes in the plasma levels of the major nutrients. Apart from this, 
the insulin secretion can be up-regulated by several intestinal hormones such as 
insulin, glucagon-like-peptides (GLP-1), gastric inhibitory peptide (GIP), secretin 
and CCK, as well as by vagal and p_adrenergic stimulation. Insulin secretion is 
also under control of somatostatin and enhanced a-adrenergic activity, as well as 
physiological conditions like fasting and exercising (Widmaier et al., 2005). 
P cells are capable of taking up metabolized glucose, galactose and mannose of 
each can provoke insulin secretion by islets. The mechanism that a glucose 
molecule stimulates the release of insulin can be explained by an established 
concept called glucose-stimulated insulin secretion (GSIS; see Figure 1.3). 
Glucose enters the p-cell via a membrane-bound glucose transporter, termed 
GULT2; once within the p-cell, glucose undergoes the chain reaction of glycolysis 
leading to the production of adenosine triphosphate (ATP). The resultant increase 
in the ratio of ATP to ADP inhibits the ATP-sensitive K+ channel and thus the 
depolarization of K+ channel activates the voltage-gated Ca:+ channel. Finally, a 
12 
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blood. 
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Figure 1.3 Schematic diagram of glucose-stimulated insulin secretion (GSIS) 
[Extracted from Fauci AS, Kasper DL，Braunwald E, Hauser SL, Longo DL, Jameson JL, 
Loscalzo J. Harrison 's Principles of Internal Medicine, 17从 edition. 
Http://www. accessmedicine. com] 
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1.2iype 1 Diabetes 
1.2.1 Pathophysiology of Diabetes Mellitus 
Diabetes mellitus refers to a condition when the body fails to maintain normal blood 
glucose homeostasis. The prolonged high blood glucose level, which is also known as 
hyperglycemia would ultimately lead to diabetes mellitus. According to the 
guidelines from The American Diabetes Association (ADA, 2009), normoglycemia, 
impaired glucose tolerance (IGT, also known as pre-diabetes), and overt diabetes 
mellitus can be distinguished based on fasting plasma glucose (FPG) levels and 
2-hour oral glucose tolerance test (OGTT). Details are shown in Table 1.1. 
Individuals with impaired FPG or IGT are generally euglycemic, but have normal 
glycated hemoglobin levels (HbAic) ranging from 3.5-5.5%. They may progress to 
overt diabetes if not treated. According to the World Health Organization (WHO), 
there are more than 220 million people worldwide having diabetes and this figure is 
likely to be more than double by the year of 2030 (WHO, 2009). In view of this, the 
epidemic of diabetes has a profound economic impact on our community. Patients 
with diabetes always experience polyuria, polydipsia and polyhagia, and these 
symptoms are concomitant with several chronic complications such as nephropathy, 
retinopathy and neuropathy, which eventually lead to renal failure, blindness and 
14 
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diabetic foot, respectively. 
Diabetes mellitus is generally classified as type 1 (TlDM), type 2 (T2DM) and 
gestational diabetes melitus (GDM; ADA, 2009). The two major types of diabetes, 
namely TlDM and T2DM account for approximately 10% and 90% of diabetes, 
respectively. TlDM, previously known as insulin-dependent or juvenile diabetes, is 
characterized by the immune-mediated destruction of insulin-producing islet P-cells 
in the pancreas, leading to insulin deficiency. Most of the TlDM are 
immune-mediated, with auto-antibodies against the islet cell antigens, islet cell 
surface antigens, GAD65 and GAD67. TlDM pathogenesis is thought to involve 
both genetic susceptibility and environmental factors. T2DM, previously known as 
non-insulin dependent or adult-onset diabetes, is characterized by the defective 
responsiveness ofperipheral tissues to insulin or, more specifically, insulin resistance, 
along with reduced insulin secretion. T2DM represents the predominant form of 
diabetes among all cases. The etiology of T2DM is multifactorial and it is strongly 
associated with genetic and environmental disposition. The most frequent monogenic 
T2DM form is the autosomal dominant diabetes called maturity onset diabetes of the 
young (MODY). The majority of proteins associated with MODY are transcription 
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factors, such as hepatocyte nuclear factor 4a (HNF-4a), insulin promoter factor-1 
(IPF-1) and NEUR0D1 that directly or indirectly influence the expression of insulin 
genes (Malecki, 2005). There are so far six MODY identified, namely MODY 
1,2,3,4,5 & 6, depending on the specific gene involved. 
2-hour Oral Glucose Fasting Plasma 
Condition Tolerance Test (OGTT) Glucose (FPG) 
— mmorn(mgAil) mmol/l(mg/dl) 
Normal <7.7 (<140) <6.0 (<110) 
Impaired Glucose >7.8(>140)&<11.1(<200) >6.0(>110)&<7.0(<125) 
Tolerance (IGT) 
~~Over t Diabetes >11.1(>200) >7.0 (>125) 
Mellitus 
Table 1.1 Diagnosis of pre-diabetes and diabetes by Fasting Plasma Glucose (FPG) and 
Oral Glucose Tolerance Test (OGTT). [Informationfrom: ADA, 2009] 
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1.2.2 Autoimmunity in TlDM 
TlDM is considered to be a chronic immune-mediated disease characterized by 
selective destruction ofinsulin-producing P-cells in the pancreatic islets. Studies have 
shown a subclinically prodromal period in these susceptible subjects. The cause of 
TlDM can be briefly classified into humoral and cellular autoimmunity ofwhich the 
immune system is related. It has been widely accepted that cellular immune 
responses is the major mediator of P-cell destruction. Although the exact mechanisms 
involved in the initiation and progression of P-cell destruction are yet understood, 
reports revealed that p-cell autoantigens, macrophages, dendritic cells, B 
lymphocytes, and T lymphocytes are involved in the p-cell-specific autoimmune 
process (Rossini et al., 1993; Bach, 1995; Tisch & McDevitt, 1996; Delovitch & 
Singh, 1997; Yoon & Jun, 1999). Figure 1.4 outlines the possible etiology ofTlDM. 
Autoreactive T cells, both CD4+ and CD8+ T cells, have been proved to be critically 
participated in p-cell destruction (Yoon & Jun，2005). This is supported by the 
presence of autoreactive T cells in the circulation of patients with TlDM and the 
disease progression can be delayed by the use of T cell targeted immuo-suppressive 
drugs (Roep, 2003). There are two proposed mechanisms of cellular mediated P-cell 
death: the recognition-linked mechanism suggests that the direct T cell/p-cell contact 
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leads to the recognition of autoantigens by cytotoxic CD8+ T cells and MHC 
molecules on the p cell surface, and alternatively, the activation-linked mechanism 
proposes that the recognition ofantigens presented by MHC II molecules leads to the 
production ofcytokines and death mediators by CD4+Tcells. 
On the other hand, the humoral immune system plays a role in TlDM. This is 
evidenced by the fact than more than 90% of TlDM patients have autoantibodies 
against one or several p-cell-specific autoantigens (Schranz & Lemmark, 1998) such 
as glutamic acid decarboxylase (GAD65), the protein tyrosine phosphatase-related 
islet antigen 2 (IA-2), insulin and, most recently, the zinc transporter Slc30A8 that is 
resided in the insulin secretory granule of the p cells (Todd et al, 2007). The most 
susceptible genes that contribute to the disease are located at the HLA class II locus 
on chromosome 6. However, additional factors are required to trigger and drive 
p-cell destruction in genetically predisposed subjects since only a small proportion 
of individual with HLA susceptibility develops into clinical diabetes (Knip & 
Siljander, 2008). 
Despite the intensive investigations into the cause of autoreactive P-cell destruction, 
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the initial activation of autoreactive T-cells and/or the presence of the primary 
autoantigen remain largely controversial. 
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Figure 1.4 Etiology o fT lDM 
[Extractedfrom: Yoon JW, Jun HS. Autoimmune destruction ofpancreatic beta cells. Am J 
Ther.;12(6):580-9L 2005] 
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1.2.3 Management of TlDM 
1.2.3.1 Insulin replacement 
Given the lack of endogenous insulin production in TlDM patients, the injection 
of exogenous insulin together with the strict monitoring of glycemia remains the 
current treatment for TlDM. While the intensive insulin regimen has been proved 
to be effective to delay and prevent disease progression to nephropathy, neuropathy 
or retinopathy (The Diabetes Control and Complications Trial, 1993), the 
intensification of insulin regimen actually leads to an increased risk of severe 
hypoglycemic episodes and low patient compliance with the intensive injection 
scheme. Therefore, the development of alternative therapies for TlDM is in 
desperate need to solve these problems as well as alleviating the long-term insulin 
dependence for patients with TlDM or severe form ofT2DM. 
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1.2.3.2 Pancreas and islet transplantation 
Given the challenges and limitations of exogenous insulin therapy, alternate 
solutions including whole pancreas and islet transplantation have been sought. 
Simultaneous pancreas and kidney transplantation is currently regarded as the 
standard therapy for TlDM patients with end-stage renal failure. Though pancreas 
transplantation achieves insulin independent in over 80% patients beyond a year 
(Sutherland et al., 2001), the risk associated with surgical procedures is always 
concerned. In contrast, islet transplantation is relatively safer than whole pancreas 
transplantation in terms of its non-invasive approach. A successful rate of 100% 
was noted in 7 long-term diabetic patients by the Edmonton Protocol in 2000, 
using a new immunosuppressive regimen and at least 10,000 islets obtained from a 
minimum of two donor pancreases (Shapiro et al., 2000). Patients having 
undergone islet transplantation have a remarkable improvement in life style which 
allows them to be independent from daily insulin injection and tight glycemic 
control. However, both pancreas and islet transplantation are hindered by life-long 
immunosuppression, organ scarcity and difficulties in islet isolation. 
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1.2.3.3 Stem-cell-based transplantation 
While the shortcomings of pancreas and islets transplantation are yet to be 
overcome, the discovery of pluripotent stem cells as an inexhaustible source of 
precursor cells that can be differentiated into insulin producing cells provides the 
prospective for islet transplantation. Figure 1.5 highlights the generation of insulin 
expressing cells from different sources of pluripotent stem cells and organ specific 
progenitors. There are numerous potential sources of undifferentiated 
stem/progenitor cells that are capable of differentiating into insulin-secreting cells, 
including pancreas, liver, intestine, spleen, bone marrow and umbilical cord as well 
as embryonic stem cells (Lu et al., 2007). 
The notion of the existence of pancreatic stem/progenitor cells within the 
pancreatic ductal cells, despite being contentious, is supported by substantial data. 
During embryogensis, stem cells within the pancreatic duct epithelium give rise to 
both endocrine and acinar cells of pancreas (Madsen et al., 1996) and the capacity 
to be expandable and differentiable still retain in adult pancreatic duct cells. 
Studies have demonstrated using pancreatic ductal epithelial cells extracted from 
non-obese diabetic QSfOD) mice (Ramiya V.K., et al., 2000)，neonatal rats (Ogata et 
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al., 2004) could produce insulin producing cells and reverse diabetes in different 
diabetic mouse models. Recently, the protocols for isolating, characterizing and 
culturing pancreatic progenitor cells (PPCs) from human fetus were reported (Hori 
et al,, 2008, Koblas et aL, 2008). A differentiation cocktail was avaliable to direct 
PSCs into hormone-producing ICCs (Suen et al., 2008). With the propensity to 
differentiate and lower immunogenicity compared with adult tissues, PPCs become 
another promising source for stem cell transplantation. 
Embryonic stem (ES) cells are also promising source for p cell. In this regard, 
some research groups have generated islet-like clusters from mouse ES cells 
through either a five-step (Lumelsky et al., 2001) or three-step (Schroeder et al., 
2006) culture protocol. The clusters were glucose responsive and were able to 
exhibit vascularization upon transplantation. A normalization of glycemia was 
demonstrated in STZ-diabetic mice. However, achieving transplantable p-cells 
from ES cells is still in development and researchers are working to optimize the in 
vitro protocol. Prior to clinical application, it is also important to note the risks of 
teratoma formation from undifferentiated ES cells residues due to their oncogenic 
nature (Evans & Kaufman, 1981). 
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In addition, a subset of enteroendocrine cells called K cells was initially 
investigated for their ability to produce a glucose-dependent insulinotropic 
polypeptides that potentiate insulin release postprandially. In this context, it has 
been shown that using intestinal tumor cell line transfected to produce insulin can 
reverse the hyperglycemic condition of STZ-induced diabetic mice. (Han et al., 
2007) 
Stem-cell based therapy holds great promise in treating diabetes. However, there 
are controversies and challenges that have yet to be solved, especially the 
yet-to-be-modified protocol to generate fully mature and rich insulin-producing 
P-cells from different cell sources and the low efficacy of islet transplantation in 
terms of poor vascularization and immuno-rejection. Improvements on these 
aspects are likely to shape the future of cell-based diabetic therapy. 
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Figure 1.5 Generation of insulin-expressing cells from pluripotent cells and organ-specific 
progenitor cells. 
[Extracted and modified from: Aguayo-Mazzucato C, Bonner-Weir S. Stem cell therapyfor 
type 1 diabetes mellitus. Nat Rev Endocrinol 6(3):139-48. 2010] 
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1.3The adaptive immune system 
1.3.1 T-lymphocytes 
T lymphocytes, or T cells, is a type of white blood cells that has central role in 
cell-mediated immunity. The abbreviation "T" stands for the organ, thymus, in which 
T cells undergo maturation. T cells can be differentiated from other lymphocytes by 
its presence ofunique T cell receptors (TCR) on the cell surface. Different subsets of 
T cells, including T helper cells, cytotoxic T cells, memory T cells, regulatory T cells, 
natural killer T cells as well as gamma delta T cells have been discovered which 
display respective processing distinct functions. 
The major function o f T helper cells, which is also known as CD4+ T cells, is to assist 
other white blood cells in immunological processes including the maturation of B 
cells into plasma cells, as well as the activation of cytotoxic T cells and macrophages. 
T helper cells are activated upon the presentation of peptide antigens by the major 
histocompatibility complex (MHC) class II molecules on antigen presenting cells 
(APCs). Once activated, T helper cells could differentiate into one of several 
subtypes, such as Thl and Th2, that secrete different cytokines to facilitate different 
types of immune response. 
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On the other hand, cytotoxic T cells (also known as CD8+ T cells) are rather 
destructive in nature that can destroy virally infected cells and tumor cells, and they 
are also responsible for transplant rejection. NaiVe cytotoxic T cells are activated 
when their TCR recognized the antigens associated with MHC class I molecules. 
Upon activation, cytotoxic T cells undergo clonal expansion and travel throughout 
the body in search for cells bearing the target antigen. When exposed to the target 
cells, cytotoxic T cells release perforin and granulysin to lyse the cells. They also 
release granzyme that enters cells via pore to induce apoptosis. The activation of 
cytotoxic T cells is under a tight control and requires a strong activation signal from 
MHC molecules or helper T cells to prevent an extensive damage to cells and tissues. 
The sole antigen-specific signal from the interaction between TCR and peptide-MHC 
molecules is actually inadequate to attain full activation of T cells. Indeed, a second 
signal, referred as the co-stimulatory signal, is provided by the interaction between 
co-stimulatory molecules on both APCs and T cells. CD28 is the co-stimulatory 
molecules expressed on T cells, which interacts with CD80 and CD86 on the 
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1.3.2 B-lymphocytes 
In contrast to T cells, B cells are type of lymphocytes that play a main role in 
humoral immune response. In mammals, the abbreviation "B" stands for bone 
marrow where they are originally produced. The principal functions of B cells are to 
produce antibodies against antigens, perform as antigen-presenting cells, and to 
develop into memory B cells upon activation. Each B cells process a receptor protein, 
referred to as B cell receptor, on its surface that can bind to one specific antigen. 
Once B cells encounter its cognate antigen, with the additional signal from T helper 
cell, it can further differentiate into plasma B cells and memory B cells for the 
production ofantibodies. Most activation o f B cells is T-cell dependent, meaning that 
the activation requires the co-stimulation provided by T cells after B cells have 
ingested and processed an antigen and presented onto its own MHC molecules to the 
T cells. However, some antigens, such as the epitopes of bacteria, are T cell 
independent that they can deliver signals for B cell activation. The notion is 
demonstrated by the fact that athymic mice can respond to these antigens. 
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1.3.3 Major histocompatibility complex 
1.3.3.1 Classification of MHC molecules 
The immunological compatibility between donor and recipient is governed by the 
recognition of T cells to the molecules on the cell surface called major 
histocompatibility complex (MHC). The human leukocyte antigen (HLA) system is 
the name ofthe MHC in huma which is encoded on the short arm of chromosome 6 
at 6p21.3 consisting ofthree major linked gene clusters, namely the class I，class II 
and class III regions. The class I region encodes three classical and most well 
known molecules HLA-A, B and C. Class I molecules are found to be expressed on 
most nucleated cells. In addition, three non-classical class I molecules HLA-E, F, 
and G are also encoded in the HLA class I region. In contrast to HLA-A, B and C, 
these non-classical class I molecules have distinct patterns of tissue expression. For 
instance, the expression of HLA-G is considerably high in trophoblast and is found 
to be important for protecting the fetus from the triggering of matemal immune 
response (Le Bouteiller, 2000). On the other hand, the class II region encodes the 
MHC class II molecules, including HLA-DR, DQ and DP. The expression of 
class II molecules is much more limited compared with class I, where 
expression is mainly distributed on professional APCs such as B cells, 
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macrophages and dendritic cells. The class III region comprises a diverse 
collection of genes such as complement components and tumour necrosis factors 
(TNF) a and P. Though numerous other genes are discovered in this region, 
their functions have yet to be confirmed. 
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1.3.3.2 Structure ofMHG class I and II molecules 
The structure of MHC class I and class II molecules are biochemically distinct 
on the basis oftheir subunits as shown in Figure 1.7. A MHC class I molecule 
consists of a large a-chain associated non-covalently with the smaller 
P2-micr0gl0bulin, with which only the a chain spans the membrane. Whereas a 
MHC class II molecule consists of two transmembrane glycoprotein chains, a 
and P, both of which are non-covalently associated with the cell surface. The 
structures of MHC class I and class II molecules are similar in such a way that 
each molecule contains an extracellular portion composed of four domains. The 
membrane distal domains fold together to form a long groove while the rest of 
the extracellular portion adopts an immunoglobulin-domain-like structure. 
Despite their similarity, there are many minor structural differences that render 
the difference in the way they interact with peptide antigens. 
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Figure 1.7 Structure o f M H C class I and II molecules. PBR=protein binding region. 
[Extractedfrom: the Annual Review of Genetics, Vol 32 ©1998 hyAnnual Reviews, 
www. annualreviews. org] 
33 
CHAPTER 1 INTRODUCTION 
^ ^ ^ ^ ^ = ^ ^ = ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ™ ' ^ ^ ™ = ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ 
1.3.3.3 Function and regulation ofMHC molecules 
The central role of MHC molecules is the presentation of antigens to T 
lymphocytes. Unlike B cells which recognize the native form of antigen, T cells 
are specific for the recognition of short peptide fragments that are derived by the 
proteolytic cleavage of intact antigens, and which are then presented by MHC 
molecules to T cell receptor (TCR) (Bevan, 1975). Hence the antigen 
recognition of T cells is restricted to MHC and the antigen peptide that it 
presents. Two forms of mature T cells, namely CD4+ and CD8+ T cells are 
restricted to MHC class II and class I molecules, respectively. 
The two major classes of MHC molecules possess very different patterns of 
tissue distribution. MHC I molecules are widely expressed on different tissues. 
As mentioned above, the expression ofMHC II molecules are much stricter than 
that ofclass I. MHC class II are expressed exclusively on professional APC such 
as B lymphocytes, macrophrages and dendritic cells. Nevertheless, MHC Class 
II expression can somehow be induced in tissues which are otherwise negative 
for class II under pathological conditions. For instance, in patient with TlDM, 
class II expression was observed in P-cells of the pancreatic islet tissue 
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(Bottazzo et al 1985). Meanwhile, the expression of class I and II genes can be 
induced or up-regulated by certain immune mediators such as interferons 
(Collins et al. 1984; Pujol-Borrell et al. 1987) and TNF-a (Collin et al. 1986; 
Arenzana-Seisdedos et al. 1988). 
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1.3.4 HLA-G and its immuno-modulatory properties 
HLA-G is the best studied ofthe three non-classical MHC molecules that play a key role 
in the induction of immune tolerance. It is categorized as non-classical because of their 
difference with classic MHC I molecules by its genetic diversity, expression, structure 
and functions (Carosella et al., 2008). HLA-G has a very low polymorphism with only 8 
protein variants compared with 462 and 789 for HLA-A and -B, respectively (Carosella 
et al., 2008). On the other hand, the expression of HLA-G is highly restricted to fetal 
trophoblast cells (Kovats et al., 1990), and is constitutively expressed in adult thymic 
medulla (Mallet et al., 1999), comea (Le Discorde et al.，2003), pancreatic islet (Cirulli 
et al., 2006) and erythroid and endothelial-cell precursors (Menier et al., 2004). 
Expression of HLA-G is induced in several pathological conditions such as cancers, 
transplantation, multiple sclerosis, inflammatory disease and viral infections (Carosella 
et al., 2008). The HLA-G primary transcript is spliced in seven messenger RNAs 
(mRNAs) that encode four membrane-bound (HLA-G1, -G2, -G3 and -G4) and three 
soluble (HLA-G5, -G6 and -G7) protein isoforms (Figure 1.8). 
Given the nature of trophoblast that makes up the physical matemal-fetal interface, the 
localized HLA-G expression on placental trophoblast cells implies a critical role in the 
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maternal immune accommodation of the semi-allogeneic fetus. Table 1.2 depicts the 
inhibitory effect ofHLA-G on different types of cells. The underlying mechanism lies in 
the capability of HLA-G to bind inhibitory receptors, called the leukocyte 
immunoglobulin-like receptors (ILTs), that interferes with leukocyte activation. HLA-G 
molecules are capable of inhibiting the cytolytic function and proliferation of NK cells 
and cytotoxic T lymphocytes as well as the maturation and function of dendritic cells 
(Carosella et al., 2008). The expression ofHLA-G protein was previously demonstrated 
in some human melanoma cell lines. Several reports have demonstrated the capacity of 
interferons, GM-CSF, IL-2 and IL-10 in the enhancement of HLA-G protein expression 
(Carosella et al., 1999). 
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Figure 1.8 Primary transcript and isoforms ofHLA-G 
[Extractedfrom: Carosella ED, Favier B, Rouas-Freiss N, Moreau P, Lemaoult J. Beyond 
the increasing complexity of the immunomodulatory HLA-G molecule. Blood. 
111(10):4862-70. 2008] 
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Effectorcell HLA-Gfunction 
、 ‘ ‘ -- .： .. ’, •、 ,...'.：..:'.'... -" ……‘ 
Inhibition of cytotoxic function 
Indirect inhibition ofcytotoxic function through stabilization of 
cell-surface HLA-E 
Inhibition of proliferation 
NK cells Up-regulation of inhibitory receptors 
Apoptosis 
Increased proliferation and IFN-y production 
Increased secretion of pro-angiogenic factors 
Inhibition of transendothelial migration 
Inhibition of cytotoxic function 
+ Inhibition of proliferation 
Generation of CD8-low regulatory T cells 
Apoptosis 
Inhibition of alloreactivity 
Inhibition of proliferation 
CD4 T cells 
Up-regulation of inhibitory receptors 
Generation ofregulatory T cells, including CD4-low T cells 
Inhibition of dendritic cells maturation, antigen presentation, 
APC trafficking, and induction of regulatory T cells 
Up-regulation of inhibitory receptors 
PBMC Secretion of Th2 cytokines 
Endotheiiai cells Apoptosis 
Table 1.2 The inhibitory effect of HLA-G on various kinds of cells. [Extract and modified 
from Carosella ED, Favier B, Rouas-Freiss N, Moreau P, Lemaoult J. Beyond the 
increasing complexity of the immunomodulatory HLA-G molecule. Blood. 
111(10):4862-70. 2008] 
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1.4Transplantation rejection 
1.4.1 Mechanisms involved in transplantation rejection 
Allogeneic grafts are inevitably subjected to immune rejection triggered by both the 
innate and adaptive immune system. The immune responses is mediated by the 
disparate antigens present on the donor tissues or cells, which can be categorized into 
three major groups including human ABO blood group antigens, HLA molecules and 
the minor histocompatibility complex (mHC; Bradley et al., 2002). The ABO 
antigens are expressed on almost every cell in the body. The transplantation of 
vascularized organs between incompatible individual can lead to hyperacute rejection, 
which is mediated by antibodies directed toward the ABO-incompatible antigens. 
Although the expression of ABO antigens on stem cells are not known, it is advised 
to avoid ABO imcompatibility when transplanting stem-cell derived products, 
especially for non-vascularized tissue allografts such as pancreatic islets (Bradley et 
al., 2002). 
Apart from ABO antigens, HLA-disparities between donor-recipient pair should be 
the most formidable immunological barrier to transplantation. The central role of 
MHC molecules is the presentation of antigens to T lymphocytes for triggering 
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immune responses. Minor histocompatibility complex (mHC) antigens are 
comparatively less remarkable but their effects cannot be completely discounted as 
they may initiate immune responses when exist in large number (Simpson et al., 
2001). 
1.4.2 Immunobiology of rejection 
Allorecognition refers to the ability of recipient T cells to recognize donor-derived 
antigens that initiates immune responses. This can be divided into two distinct 
pathways, namely the direct and indirect pathway (as shown in Figure 1.9). Both 
depend on the presentation of donor cell antigens. In the direct pathway of 
allorecognition, T cells recognize intact non-self MHC molecules present on the 
surface of donor cells; whereas indirect pathway describes the ability of T cells to 






1.4.2.1 Direct allorecognition pathway 
In the direct recognition (Figure 1.9 left), the APCs that exist in the donor tissue, 
upon transplantation, migrate to the nearest lymphoid system to trigger host 
immune response. Evidences have shown that dendritic cells (DCs) are the 
passenger leukocyte responsible for the induction of an acute anti-allograft 
response (Fung et al., 1985). DCs are abundant within peripheral tissues and 
organs in their mature state positioned for antigen capturing. These cells would 
undergo a mature process upon the stimulation of inflammatory signals such as 
interleukin (IL-1 p) and tumor necrosis factor (TNF-a), and migrate to the lymph 
nodes for the activation ofnaive memory T cells (Archbold et al., 2008). T cells 
mistakenly interpret the donor MHC/peptide complex on DCs as self-MHC with 
. a foreign peptide, and together with co-stimulation, resulting in T cell activation 
(Grirmemo et al., 2008). The graft-specific T cells then infiltrate to the graft by 
recognizing directly to the alloantigens on the graft parenchyma. Direct antigen 
presentation is the pathway that induces the strongest immune responses. 
J Nevertheless, cellular transplant usually do not contain donor APCs and the 
E rejection of cellular grafts are less likely to be induced by direct recognition 
E. f 
k 
I pathway (Grinnemo et al., 2008). 
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1.4.2.2 Indirect allorecognition pathway 
The concept of indirect allorecognition pathway (Figure 1.9 right) were 
proposed upon the rationale that the DC population in the transplanted graft 
would decline with time and that chronic rejection can only be explained by an 
indirectly pathway in which recipient DC take up and process alloantigens and 
then present it via self-MHC class II molecules to CD4+ cells in local lymphoid 
tissues (Caballero et al., 2006). Some antigens of the grafts may also be 
presented to CD8+ T cells via class I MHC pathway. (Grinnemo et al., 2008). 
1.4.2.3 Semi-direct allorecognition pathway 
Apart from that generation of antigen-specific CD8+ cells requires the activated 
CD4+ T cells, climbing researches have demonstrated the participation of DCs in 
the allorecognition responses. Evidences have shown that MHC molecules can 
be transferred between cells, the recipient DCs are capable of taking up and 
presenting intact donor MHC class-I molecules to directly stimulate CD8+ T 
. cells, and at the same time internalized and process donor MHC molecules as 
peptides to CD4+ T cells with indirect allospecificity. The exploration of this 
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of grafts derived from stem cells that are usually devoid of DCs but not 
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Figure 1.9 Direct and indirect T-cell recognition pathways. 
[Extracted from: Archbold JK，Ely LK，Kjer-Nielsen L, Burrows SR, Rossjohn J， 
McCluskey J, Macdonald WA. T cell allorecognition and MHC restriction-A case of 
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1.4.3 Xenotransplantation 
Xenotransplantation is the transplant of organ or tissue from one species to 
another. Though it might seem impossible in first sense, the highly successful 
incidence in transplantation of porcine heart valves has proved 
xenotransplantation a new ground for organ or tissue replacement for human. 
Unfortunately, xenotransplant is often dangerous due to the high risk of 
incompatibility oftissue antigens, rejection and viral infection from one species 
to another. Although the attributes to xenorejection are numerous, the cellular 
response is primarily T cell mediated (Sachs et al., 1990). In a study, the transfer 
of blood cells enriched with CD4+ T cells into allografts or xenografts 
transplanted to athymic BALB/c mice showed that graft rejection occurred 
sooner in xenotransplant than in allotransplant, whereas the transfer of CD8+ T 
cells were ineffective in rejecting either types of grafts. Data suggest that 
xenorejection is CD4+ T cell dependent, and its mechanism is distinctive from 
that of allograft rejection (Mandel, 1999). The selective dependence of 
xenorejection on CD4+ T cells were also demonstrated in other models using 
skin (Pierson et al., 1989) and pig islet tissues (Mandel et al., 1990; Mandel et 
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cells destroy xenografts are yet understood (Morris et al., 1995; Yi et al., 2002). 
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1.5 Cytokines and immunity 
1.5.1 Interferons 
Interferons (IFNs) is a kind of glycoproteins originally discovered as an agent that 
interferes with viral replication (Isaacs & Lindenmann, 1957). They are produced by 
cells of the immune system in response to challenges by foreign agents such as viruses, 
parasites and tumor cells. There are three main types of IFNs, including IFN type I, II 
and III, by which the classification is accorded with their receptor specificity and 
sequence homology. It is surprising to observe that IFNs, instead ofbeing an antiviral 
molecule alone, are actually capable of inducing massive de-repression of the cellular 
genome and stimulating expression of a large number of cellular genes of many 
different functional categories. This indicates that IFNs participate in a diversity of 
cellular functions and many of the mechanisms have yet to be elucidated. 
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1.5.1.1 Interferon-y and its immune regulation 
IFN-y is designated as "immune" or type IIIFN and is produced by leukocytes.. 
Though both type I and II of IFN are crucial in the immediate cellular response 
to viral infection, IFN-y is more important in coordinating the later immune 
response and establishing an antiviral state for longer term control. 
IFN-y is able to orchestrate the trafficking of specific immune cells to the site of 
inflammation through up-regulating the expression of adhesion molecules and 
chemokines. At the site of inflammation, IFN-y and NO are produced, causing 
local dilation of blood vessels, thus decreasing the local blood flow. Hence, the 
unstimulated leukocytes that are originally cycling between blood and lymph 
would gather at the leaky vessels. Many reports has suggested that IFN-y arrests 
the macrophage cell cycle and provides a survival signal, while other suggested 
that it serves as a pro-apoptotic signal (Schroder et al., 2004). The antiviral, 
antiproliferative and immunoregulatory effects the IFN-y exerts on cells were 
believed to be mediated by a set of genes induced by the cytokines. Table 1.3 
showed different categories of genes or proteins regulated by IFN-y. The 
primary signaling pathway activated by IFN-y has been known as Janus Kinase 
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(JAK)-STAT pathway. Given the complexity and diversity of IFN-y as an 
immune modulator, we would therefore focus on its effects on the expression of 
MHC molecules as well as the regulation ofIFN-y production upon stimulation. 
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Gene/protein Function 
up-regulated by IFN-y 
MHC antigen Processing and Presentation 
The heavy chain associates with p2-microglobulin to form the 
MHC class I complex (MHC I). MHC I displays foreign and 
Class I MHC heavy self-peptides on the cell surface for immune surveillance by 
ch^ aixx 
cytotoxic T cells. The class I heavy chain is encoded by the 
class I MHC locus. 
Proteasome activator (PA)28a:PA28 P dimer is a 
PA28 oc, PA28 P nonenzymatic proteasome subunit, which alters the specificity 
of peptides generated to increase efficiency of class I MHC 
peptide delivery. 
Constituents of the heterodimeric MHC II. MHC II displays 
a l , a 2 , p i , p 2 foreign and selfpeptides on the cell surface for immune 
MT4�TT rhain<? 
surveillance by CD4+ T cells. The MHC II a and p chains are 
encoded by the class II MHC locus. 
Lysosomal proteases implicated in peptide production for class 
CathepsinsB,H,L j i^HCloading . 
Activation ofMicrobiaI Effector Functions 
The NOS enzymes ^sfOSl, iNOS, NOS3) catalyze the reduced 
nictonimide adenine dinucleotide phosphate 
NADPH)-dependent conversion of L-arginine to L-citrulline, 
iNOS/NOS2 forming NO as a by-product. Of these, iNOS is the only 
- isoform inducible by cytokine and/or microbial stimulus. 
Complement proteins are secreted by macrophages and 
fibroblasts in response to IFN-y. Complement functions to 
opsonize extracellular pathogen for receptor-mediated 
C2,C4,FactorB ^ ^ . ^ , , ^ 
phagocytosis by mononuclear phagocytes. 
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Immunomodulation and Leukocyte Trafficking 
Adhesion molecule-binding to lymphocyte function-associated 
ICAM-1 antigen-1 and Mac 1. 
Vascular cell adhesion Adhesion molecule-binding to very late antigen-4. 
molecule-1 (VCAM-1) 
Surface molecule on APCs that provide a costimulus for 
B7 2 
‘ antigen-specific T cell activation. 
MIP-la, MIP-ip chemoattractant for CD4+, CD8+, and memory T cells. 
(CCL3, CCL4) 
Table 1.3 Some highlighted genes or proteins regulated by IFN-y. [Extract and modified 
from Schroder K, Hertzog PJ, Ravasi T, Hume DA.Interferon-gamma: an overview of 
signals, mechanisms and functions. JLeukoc Biol 75(2):163-89. 2004J. 
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1.5.1.2 Effect and kinetics of interferon-y on MHC molecules expression 
IFN-y has been discovered to be involved in the up-regulation of both MHC 
class I and II molecules. This is of crucial significance to increase the quantity 
and diversity of peptides presenting on cell surfaces and thus potentiating the 
antigen recognition o f T cells in order to induce cell-mediated immune response 
upon pathogen invasion. Regardless the cognate o f M H C I and II molecules, the 
kinetics of IFN-y induced expression of the two classes are different in terms of 
the signaling molecules involved. 
The known IFN-y signal transduction pathway inducing the expression o f M H C 
I and II molecules are demonstrated in figure 1.10. Upon the binding ofIFN-y to 
its receptors, which is comprised of IFN-yRl and IFN-yR2, the signal 
transducers and activators oftranscription-1 (STAT-1) is phosphorylated by the 
activated JAKl/2, followed by STAT-1 homodimerization. The dimerized 
STAT-1 then translocates to the nucleus to bind to the IFN-y activation site (GAS) 
to initiate the transcription of interferon regulatory factory-1 (IRF-1). For the 
induction of MHC class I molecules, IRF-1 regulates the transcription of 
interferon-stimulated genes (ISGs) on IFN-stimulated response elements (ISRE), 
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leading to the transcription of several MHC class I related genes. On the other 
hand, apart from inducing IRF-1, the dimerized STAT-1 itself also binds onto the 
GAS promoter regions to induce the transcription of CIITA. Its protein would 
induce the MHC-II expression on cell surface for the activation o f T cells. 
The IFN-y inducible components are not restricted only to the MHC molecules 
itself but also genes that are related to the processing and presentation of 
peptides. For instance, apart from the induction of the expression ofheavy chain 
and the light chain of MHC-I (Decker et al.，2002), IFN-y induces the new 
subunits, LMP2, MCL-1 and LMP7, which can competitively replace the 
original subunits of the proteasome (Belich et al., 1994; Hisamatsu et al., 1996; 
Nandi et al., 1996). This proteasome replacement is one of the suggested 
mechanisms to increase the quantity, quality and repertoire ofpeptides for class 
I MHC loading. Likewise, some accessorizing molecules, such as the lysosomal 
proteases cathepsins which functions to produce antigenic peptides for class II 
MHC loading, are also induced by IFN-y. 
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Figure 1.10 MHC I and II induction through IFN-y signal transduction pathway 
[Extractedfrom: Chan WK，Lau AS, Li JC, Law HK，Lau YL, Chan GC. MHC expression 
kinetics and immunogenicity of mesenchymal stromal cells after short-term IFN-gamma 
challenge. Exp Hematol 36(11):1545-55. 2008] 
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1.5.1.3 Regulation of interferon-y production 
The NK cells and subsequently CD4+ T cells are classically well known as the 
two main sources to produce IFN-y. Although the precise mechanism is yet to be 
elucidated, it was proven that the transcription factors, such as signal transducer 
and activator or transcription 4 (STAT-4) and T-bet (Frucht et al., 2001) are 
involved. Briefly (Figure l . l la) , APCs such as dendritic cells and macrophages 
produce interleukin-12 (IL-12) to induce the production of IFN-y by NK cells 
and direct the differentiation of naiVe CD4+ T cells into IFN-y producing T 
helper 1 (Thl) cells (Trinchieri et al., 1998). IFN-y, in tum, enhances the 
antigen-presentation of DCs and macrophages to promote the killing of 
intracellular pathogens in the macrophages. This positive feedback crosstalk 
between CD4+ T cells and APCs allows the potent response to infection. 
Recent studies have also suggested the production ofIFN-y by APCs themselves 
(Frucht et al., 2001; figure l . l lb) , in which the production ofIL-12 and IL-18 
synergistically induce the production of IFN-y in an autocrine manner in these 
APCs, thus contributing to the enhancement of immunity against pathogens 
before the specific recognition by Thl cells. Meanwhile, several cytokines have 
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been found to down-regulate the production of IFN-y, these include IFN-a, IL-4 
andIL-10. 
(a) Classical model 
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Figure 1.11 Classical and "jump start" model of production of IFN-y by immune 
CQlls.[Extracted from: Frucht DM，Fukao T, Bogdan C, Schindler H，0'Shea JJ, Koyasu S. 
IFN-gamma production by antigen-presenting cells: mechanisms emerge. Trends Immunol 
22(10):556-60. 2001] 
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1.5.2 Interlukins 
1.5.2.1 IL-10 and its immune regulation 
IL-10 is first described as cytokine synthesis inhibitory factor (CSIF; Fiorentino 
et al., 1989)，which is produced by murine Th2 cells to inhibit the activation and 
cytokine production of Thl cells (Moore et al., 2001). Later studies have 
revealed the broad inhibitory spectrum of IL-10. Whilst the ultimate function of 
IL-10 is to suppress inflammatory responses to prevent damage to host, this 
multifunctional cytokine actually possesses diverse effects on most hemopoietic 
cell types, including macrophages, monocytes, dendritic cells, NK cells, B cells, 
T cells, mast cells and granulocytes. IL-10 potently inhibits the cytokines and 
chemokines production in activated monocytes/macrophages (Moore, et al., 
2001). It was noted that IL-10 suppresses the production of IFN-y in 
macrophages (Flesch, et al., 1994). IL-10 also acts on macrophages and DCs to 
inhibit the activation ofThl cells (Moore, et al., 2001). 
In addition, it was revealed that IL-10 plays a key role in the differentiation and 
function of a newly appreciated type of T cells, termed as the T regulatory cells 
(Treg), which itself produce IL-10 and function to inhibit Thl and Th2-mediated 
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immune responses. The relationship adds on the complexity of the 
immuno-inhibitory profile ofIL-10 (Roncarolo et al., 2006). 
1.5.2.2 IL-10 and HLA-G 
Evidences have shown that there is an interactive relationship between IL-10 
and HLA-G, yet the whole picture has not been clearly elucidated. Hypothesis 
lies in the fact that these two molecules are working closely together to perform 
certain immuno-suppressive effects. The capability of HLA-G to modulate 
cytokine production is widely investigated. Recently, HLA-G+ Treg cells were 
identified in the peripheral blood of healthy individuals that is enriched at the 
site of inflammation (Feger et al., 2007; Huang et al., 2009). It has been 
demonstrated that the secretion of IL-10 is elevated in HLA-G+ Treg cells when 
compared with HLA-G" cells. The suppressive effect mediated by HLA-G+ Treg 
cells is IL-10 dependent (Huang et al., 2009). Some other studies also showed 
that the incubation of peripheral blood mononuclear cells (PBMCs) with either 
purified HLA-G (Kapasi et al. 2000) or soluble HLA-G (Kanai et al., 2001) 
results in the increased production ofIL-10 by PBMCs. Nilckel H. et al. showed 
that the plasma levels of IL-10 tended to be higher in patients with HLA-G+ 
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leukemias than in patients with HLA-G" leukemias (>Jiickel H. et al., 2005). The 
observations lend support to the potential regulatory effect of IL-10 production 
by HLA-G 
Likewise, emerging data have suggested that IL-10 plays a role in regulating the 
expression ofHLA-G on several cell types. It was observed in trophoblasts and 
monocytes that the expression of HLA-G can be induced by IL-10 in a 
regulatory pathway separated from other MHC class I genes (Moreau et al., 
1999). An upregulation of HLA-G by IL-10 is also observed in decidual stroma 
cells (Blanco et al., 2008) and cutaneous lymphomas (Urosevic & Dummer, 
2003). Hence IL-10 can regulate the HLA-G expression, and the regulation runs 
in an autocrine as well as a positive feedback manner. The correlation between 
HLA-G and IL-10 was also observed in stem cells, as evidenced by the 
inhibitory effect towards T cells and NK cells, and an induction ofTregs in bone 
marrow-derived MSCs was mediated through the production of soluble 
HLA-G5 in an IL-10-dependent manner (Selmani, et al., 2008). The readouts 
leave room for the investigation on the existence and function of this 
HLA-G/IL-10 axis in other type of stem cells. 
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1.6 Stem cells and their immunogenicity 
Despite being immuno-privileged compared with whole tissue transplant, the major 
obstacle of stem cells and their derivatives in the clinical use still rests on the immune 
response towards the transplanted cells. The immunological properties of different 
stem cells and the strategic manipulations to circumvent immune rejection attract 
much attentions. 
1.6.1 Embroynic stem cells 
Human embryonic stem cells (hESC) are pluripotent stem cells isolated from the 
inner cell mass of blastocysts. Differentiation protocols for many cell types, such as 
insulin producing islet cells (Kroon et al., 2008), neurons (Johnson et al., 2007; 
Carpenter et al., 2001; Reubinoffet al., 2001; Zhang et al.，2001; Schulz et a l , 2003) 
and endothelial cells (Levenberg et al., 2002) are currently available. This implies the 
potential ofhESC to treat diseases such as diabetes and Parkinson's disease. 
Undifferentiated hESC express low levels of MHC class I and no MHC class II 
molecules, whereas the spontaneous differentiation of hESC in vitro into embryoid 
bodies (EBs) achieved an increase in expression of 2-4 folds (Drukker et al., 2002). 
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Nonetheless, the expression was still below those for other somatic cells. The 
addition of cytokine IFN-y could considerably increase MHC-I expression (Dmkker 
et al., 2002; Li et al., 2004; Grinnemo et al., 2006), while neither IFN-a nor IFN_P 
had any effect. Similar stimulatory effects on MHC-I molecules were also observed 
in differentiated hESC (Andrews et al., 1987). In contrast to MHC-I, MHC-II 
molecules were absent in both undifferentiated and differentiated hESCs even in the 
present of IFN-y (Dmkker et al., 2002). It was noted that the expression of 
co-stimulatory molecules, namely B7.1, B7.2 and CD40, are also low or absent on 
undifferentiated hESC (Li et al., 2004; Grinnemo et al., 2006). In a mixed 
lymphocyte reaction (MLR), hESC failed to induce the proliferation of human 
PBMCs (Li et al., 2004). When hESC were injected into the myocardium of 
immunocompetent C57BL/6 mice, signs of rejection were observed within 3 days, 
which peaked at day 5 to 7 (Grinnemo et al., 2006). 
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1.6.2 Mesenchymal stem cells 
Mesenchymal stem cells (MSCs) are pluripotent stromal cells that can be found in 
virtually all postnatal tissue. Since MSCs can give rise to diverse lineages of cell 
types, the notion ofMSC-based cell therapy has become an emerging strategy for the 
replacement of injured tissues. A more interesting aspect about MSCs is their ability 
to induce profound immunomodulatory effects in vivo, and therefore these cells have 
been extensively exploited in clinical trials to reduce the burden of immune-mediated 
disease such as TlDM. Though much of the knowledge regarding MSCs has been 
generated from the use ofbone marrow-derived MSCs, studies have also made use of 
MSCs derived from different tissues including muscle, adipose tissue and umbilical 
cord blood (da Silva Meirelles, 2006). 
Figure 1.12 depicted the immunomodulatory effects of MSCs. The 
immunomodulatory properties were initially discovered in T cell proliferation assays, 
in which MSCs were reported to suppress T cell proliferation irrespective of donor 
source (Bartholomew et al.，2002; Le Blanc et al, 2003). MSCs can significantly 
suppress the proliferation of both CD4+ and CD8+ lymphocytes, reduce the 
expression of activation markers on PHA-stimulated lymphocytes and abrogate the 
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response of memory T-cells to their antigen (Krampera et al., 2003). Additional 
studies using a transwell culture system to separate leukocytes from MSCs 
demonstrated an inhibitory effect on leukocyte proliferation suggesting the presence 
of soluble factors from MSCs for their suppressive properties G^auta & Fibbe, 2007). 
Among the many possible candidates representing MSCs-derived suppressive 
molecules, the transforming growth factor_p (TGF_p), hepatic growth factors (HGF), 
prostaglandin (E2), and IL-10 have been found to suppress T-cell-mediated antigen 
responses in vitro (Tyndall et al., 2007). Studies showed that the expression of nitric 
oxide synthase and heme oxygenase-1 in MSCs are responsible for their 
immunosuppressive properties (Sato et al., 2007; Chabannes et al., 2007). MSCs may 
also regulate immune response through the interaction of DCs and NK cells (Abdi et 
al., 2008). Neither of these mechanisms in governing the immuno-modulatory 
properties ofMSCs is exclusive, and their relative contribution may vary in different 
experimental models. 
Due to the lack of expression of MHC class II and most co-stimulatory molecules, 
MSCs has once been regarded as hypo-immunogenic cells. However, recent studies 
suggest that MSCs may not be as immuno-privileged as once regarded O^auta et al, 
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2006). MSCs indeed express MHC-I and numerous adhesion molecules such as 
VCAM and ICAM-1. Though they are negative for MHC-II expression, 
IFN-y-stimulated MSCs were found to express MHC-II (Le Blanc & Ringden, 2007). 
It is suggestive that MSCs may only escape from the immune rejection for a short 
period (Chamberlain et al.，2007). 
65 
CHAPTER 1 INTRODUCTION 
G 
' i proliferation 
/ B ®®"® i differentiation to plasma cells 
/ t 
i proliferation + 1 OPGE2 i proliferation 
i cytotoxicity + \ ^ + i CTLformation 
^.^^^ i IFN-Y Z " \ » z — � Z^""^^Ni IFN-7, t IL4 
/^^ '^>v V ^ / W / � Z � �� ^ 關-r \ ^ ^ | k ^ ^ ^ 
to) ^ ~ c . : : : — 二 ） _ ^ ^ # ^ # ' " " 
V L ^ "KTiDo y 、 : 二 ， \^丨00y^ 零 ^^ 
NKcells ^^^;r7 / MSC % ^"^""^“^ Tcells Treg 
二二 I Of>GE2 \ OHCF iacllvatlon • 
OTGF-fi / OM-CSF \ OTGF-P • 
/ 0/L-6 \ OPGE2 A f 
1 O/L70 V T I 
r OTGF-fi ， / 11? 
idifferentiation ^ ^ ‘maturation ^ k ^ ^ ^ J , 
• 一 會 ， 嘴 ， , 
Monocytes iDCs mDCs _ , 
••» mm ^m mm 一 
Figure 1.12 Immunomodulatory effects ofMSCs. 
CTL indicates cytotoxic T cell; HGF，hepatocyte growth factor; IDO, indoleamine 
2,3-dioxygenase; PGE2, prostaglandin E2; and TGF_P, transforming growth factor p. 
[Extracted from: Nauta AJ，Fibbe WE. Immunomodulatory properties of mesenchymal 
stromal cells. Blood. 110(10):2499-506. 2007] 
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1.6.3 Neural stem cells 
The isolation and culture of neural precursor cells G^PCs) offer a new treatment 
modality for neural repair, of which they can act as a replacement therapy for the lost 
of host neural cells. Similarly, the immunogenic status of the donor cells and thus 
whether they will be rejected after transplantation are of great concern. Studies 
showed that in vitro culture of primary neural cells would results in up-regulation of 
MHC molecules (Grenier et al., 1989). A study reported a low expression MHC on 
neural cells derived from rodent striatum, however the MHC expression increased 
after differentiation with cytokine exposure (McLaren et al., 2001). It was later 
reported that only the MHC class I and II molecules, but not the costimulatory 
molecules, CD40, CD80 and CD86, increase in expression upon culture expansion 
(Odeberg et al., 2005). PBMCs were unresponsive when co-cultured with these 
vitro-expanded NSCs, hence suggesting a low immunogenicity of NSCs despite 
MHC incompatibility and high MHC expression. 
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1.6.4 Fetal stem cells 
The use of fetal stem cells has been extensively utilized in the harvest of umbilical 
cord blood haemopoietic stem cells (HSCs) and fetal neural tissue for therapeutic use. 
Of great interest is the potentially accessible source of fetal stem cells from the 
remaining fetal organs. Fetal stem cells are described as multipotent for their partially 
determined identity in which the organ they reside in. Though their potential are 
restricted than the pluripotent ES cells, fetal tissues possess distinctive biological 
properties that are ideal for transplantation. They have potential in regenerating 
damaged tissues and are capable of rapid cell growth, proliferation and differentiation. 
Fetal stem cells also demonstrated considerable reduced immunogenicity to evoke 
immunogenic responses. Recent report showed that fetal MSC did not elicit 
alloreactive T-cell proliferation and were able to suppress mitogen induced 
lymphocyte proliferation (Gotherstrom et al., 2004). Apparently, fetal MSCs possess 
all the immunomodulatory properties of adult MSCs and what makes them outshine 
adult MSCs is the greater potent in proliferation and differentiation (Gotherstrom et 
al., 2004). 
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1.6.5 Potential immuno-study in human fetal pancreatic stem cells 
As mentioned in previous section, human fetal tissues hold a great potential in 
therapeutic application due to its potent regenerative nature and its likely 
immune-privileged status. Previous trials employed fetal intestine and fetal kidney for 
transplantation (Dekel et al., 1997; Lopes et al., 2000). It was noted that in vivo 
growth and maturation of first-trimester human fetal pancreas obtained at 6-9 weeks of 
gestation, resulted in normalized glycemia of diabetic mice post-transplant (Castaing 
et al.，2001). Further studies revealed that the immunogenicity of first-trimester human 
fetal pancreatic grafts is less than that of second-trimester (Brands et al., 2008). There 
was a reduced expression of immune-related genes and less cellular infiltration after 
transplant of first-trimester fetal pancreas. Recently, our laboratory have successfully 
isolated, cultured and characterized a population of pancreatic progenitor cells (PPCs) 
derived from human fetal pancreas that are amenable to growth and differentiation into 
insulin-producing islet-like-cell clusters (ICCs). Nevertheless, their immunological 
nature has yet to be characterized. It is necessary to characterize the 
immuno-properties of PPCs, with a particular focus on the immunologic make up of 
PPCs derived from the first and second trimester. 
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1.7 Aims and Objectives ofstudy 
The procurement of fetal stem cells as a transplantable source for treating TlDM is of 
increasing interest owing to their higher proliferation and differentiation capacity as well 
as the immune-privileged status. Several studies have demonstrated the advantages, in 
terms of reduced immunogenicity, of using fetal tissues from first trimester over second 
for transplantation. 
It is hypothesized that human fetal PPCs and ICCs derived from first-trimester possess 
lower immunogenicity than that from second-trimester. The aim of this study is to evaluate 
the immunogenicity of human fetal PPCs and PPC-dereived ICCs. Other specific 
objectives are: 
1. To characterize the expression of some selected immune-related genes in PPCs and 
ICCs; 
2. To examine the effect of interferon-y on the expression on MHC molecules in PPCs 
and ICCs; 
3. To compare the in vitro immunogenicity ofPPCs and ICCs from 1'^  and 2"^ trimester; 
4. To further compare the immune rejection of ICCs from 1'^  and 2"^ trimester using a 
xenotransplantation model. 
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2.1 Isolation of pancreatic progenitors from human fetal pancreas and 
induction ofIslet-like CeII Clusters differentiation 
2.1.1 Tissue procurement 
Human fetal pancreas specimens used in this study were procured from aborted 
fetuses after surgical termination of pregnancy (STOP); they were provided and 
processed by the Department of Obstetrics and Gynecology, The Prince ofWales 
Hospital (PWH), The Chinese University of Hong Kong. Specimens were 
collected during early gestation between 9 and 15 weeks. Informed consent was 
obtained before any procedures were performed. The approval for the use of 
fetal tissue in research was obtained from the Clinical Research Ethics 
Committee (CREC-2005.461). Tissue samples were collected after the 
completion of surgical termination of pregnancy (STOP) and examined under a 
high-power dissecting microscope. Fetal tissues including stomach, pancreas, 
kidney, liver and intestine were identified and washed with sterilized saline prior 
to isolation. Pancreata at first trimester (9-llweek) and second trimester 
(12-15week) were collected and used in the study. 
2.1.2 Tissue processing and PPC culture 
The in vitro PPCs induction and ICCs differentiation are schematically 
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illustrated in Figure 2.1. Briefly, PPCs were grown from fetal pancreatic cell 
clusters isolated from fetal pancreas as previously described (Suen et al., 2008; 
Leung et al., 2009). Dissected fetal pancreas was washed with sterilized PBS. 
They were then minced and digested in HBSS containing 3mg/ml Collagenase P 
(Roach Molecular Biochemicals, Mannbeim, Germany). The vials were shaken 
vigorously at 37�C for 10-15 min. The collagenase digestion was terminated by 
the addition of GIBCO™ Hanks' Balanced Salt Solution (HBSS; Gibco Life 
Technologies Ltd., Paisley) followed by centrifugation for 5 min at 300 g. The 
digest was further washed twice by HBSS. The remaining centrifuged pellet 
containing pancreatic cell clusters were resuspended in 60mm non-treated petri 
dishes (Coming Incorporated, NY, USA) containing culture medium. The 
culture medium consisted ofRPMI 1640 supplemented with 10% fetal bovine 
serum (FBS), 20mM HEPES (Invitrogen Life Technologies, CA, USA), lmM 
sodium pyruvate, 1% penicillin/streptomycin (Gibco Life Technologies) and 
71.5uM P-mercaptoethanol (Sigma-Aldrich, St. Louis, MO, USA). Rounded, 
non adherent cell-clusters formed within 48h of incubation and were transferred 
to a new culture dish and incubated for another 48h to deplete adhering 
fibroblast. After 96h, medium was replaced with modified RPMI 1640 media 
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supplemented with 20ng/ml each of basic fibroblast growth factor (bFGF) 
(Sigma-Aldrich) and epidermal growth factor (EGF) (Invitrogen) to induce PPC 
outgrowth. Within several days cells migrated out from the cell-clusters forming 
a monolayer of cells. Upon reaching confluence, monolayers were incubated 
with 0.05% trypsin-EDTA (Invitrogen) for 6 min and the reaction was stopped 
by Phosphate Buffer Saline (PBS) and the cell suspension was centrifuged for 5 
min at 1,600 x g. The cell pellets were further washed twice by PBS. Cell pellets 
were then resuspended in the modified RPMI 1640 media supplemented with 
bFGF and EGF and were replated in a new filter-capped T75 cell culture flask 
(TPR, Trasadingen, Switzerland). PPCs were maintained up to 10 passages and 
only passages 3-9 were used for experiments in this study. 
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2.1.3 In vitro differentiation ofPPCs into islet-like cell clusters 
Differentiation of PPCs into islet-like cell clusters (ICCs) were performed as 
previously reported (Zulewski et al., 2001; Suen et al., 2008; Leung et al., 2009). 
To initiate ICC differentiation, four T75 cell culture flasks (TPP) of confluent 
PPCs were required. PPCs were trypsinized at described above and after 
washing twice with PBS, cell pellets were resuspended in serum-free 
DMEM/F12 medium containing B27, 0.05% BSA and cocktail of growth factors 
including lOnM extendin-4 (Sigma), 10 ng/ml HGF (R&D Systems), 500pM 
betacellulin (Sigma) and 10 mM nicotinamide (Sigma) in an 6-well ultra-low 
attachment plate (Corning Incorporated) for 8 days. The media was replaced 
every other day. On day 8，differentiated ICCs were handpicked by 
micro-pipettes under an inverted light microscope (Leica Microsystems, Wetzlar, 
Germany) for further experiment. For cytokine treatment, medium in the ICCs 
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Figure 2.1 Representative microscopic images showing the in vitro PPCs induction and 
ICCs differentiation. (A) A fetus is collected from Surgical Termination of Pragnancy 
(STOP); (B) The Stomach is identified, fetal pancreas is usually attached at the back of the 
stomach; (C) After digestion the fetal islet aggregates are obtained and they will round up 
within 2 days in the presence of modified RPMI 1640 medium supplemented with 10% 
FBS; (D) PPC outgrowth from these aggregates is induced in the presence of EGF and 
bFGF; (E) Monolayer of cells called PPCs are formed within several days; (F) 
Differentiation is initiated by serum-free DMEMy'F12 conditioned medium supplemented 
with cocktail of growth factors. PPC starts to aggregate within the first 24 hours; (G) After 
8 days of differentiation rounded islet-like cell clusters are formed. 
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2.1.4 Interferon-y and IL-10 treatment 
PPCs were seeded at a concentration of lxlO^ cells/well in a 6-well plate and 
waited for at least 4 hours for the attachment of PPCs. IFN-y (R&D Systems, 
Minneapolis, MN, USA) of concentrations (lOOU/ml, 200U/ml and 500U/ml) 
were added to the PPCs and were incubated for 2 days or 4 days. IL-10 
(Peprotech Inc., Rocky Hill, NJ) ofconcentrations (5U/ml, 25U/ml and lOOU/ml) 
were added to the PPCs and incubated for 2 days. Medium of differentiated 
ICCs were replaced by modified RPMI 1640 medium prior to IFN-y and IL-10 
treatment. 
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2.2 Cell culture of human placental choriocarcinoma JEG-3 ceII line 
JEG-3 cell line was kindly provided by Dr. HF Kung (Stanley Ho Centre for Emerging 
Infectious Disease, CUHK). JEG-3 cell line was cultured in DMEM medium (Gibco 
Life Technologies) containing 4500mg glucose, L-glutamine and 110 mg/L sodium 
pyruvate supplemented with 10% FBS and 1% penicillin/streptomycin. Upon reaching 
confluence, the monolayer was digested with 0.25% trypsin-EDTA (Invitrogen) for 10 
min and the reaction was stopped by PBS. The cell suspension was centrifuged for 5 
min at 300 g and was replated onto a new T75 cell culture flask (TPP). 
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2.3 RNA expression analysis 
2.3.1 RNA isolation 
Total RNA was isolated from cultured PPCs, ICCs, JEG-3, fetal pancreas and 
fetal kidney in the presence of 1 ml TRIzol® (Invitrogen) according to 
manufacturer's instructions with minor modifications. After vigorous vortex for 
cells and homogenization for fetal tissues, samples were incubated at room 
temperature for 5 min to allow complete dissociation of nucleoprotein 
complexes. Chloroform (0.2ml/ 1ml Trizol) was added to each sample. The 
mixture was shaken vigorously for 15 s and allowed to incubate for 3 additional 
minutes at room temperature. The vials were then centrifuged at 12,000 g for 15 
min at 4°C. After centrifugation, the upper RNA-containing aqueous phase was 
carefully collected and precipitated with isopropyl alcohol (lml/ 1ml Trizol®) 
and glycerol (4-8 ul/ 1 ml Trizol®) at -80¾ overnight. The next day samples 
were centrifuged at 12,000 g for 20 min at 4�C. The supernatant was discarded 
and the pellet was washed with 1ml ice-cold 75% ethanol, which was further 
centrifuged at 7,500 g for 15 min. Finally pellets were air dried for 15 min and 
dissolved in 15-20 i^l RNAase-free deionized water (Invitrogen). The aqueous 
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The amount of total RNA was quantified using a UV-spectrophotometer. 
Concentration of RNA was calculated from the value of absorbance at 
wavelength 260nm (O.D. 260) x 40 x dilution factor. The purity of RNA 
obtained was determined by comparing the ratio of O.D. 280 to O.D. 260 and 
the value fell between 1.6 and 2.0 was considered as pure (Leung et al.，2009). 
The integrity and quality of RNA were checked by RT-PCR for the 
house-keeping gene p-actin. 
2.3.2 Reverse transcriptase (RT) 
First strand cDNA was reverse transcribed using Superscript^^ III Reverse 
transcriptase (Invitrogen) according to the manufacturer's protocol. In brief, 2-3 
|Lig RNA was combined with 500 i^g Oligo(dT)188, lOmM dNTP mix to make 
up a 13 |il reaction mix. This reaction mix was denatured at 65^C for 5 min. 
After quick chill on ice for 1 min，5X first-strand buffer, O.lM DTT，40 units/^il 
RNAaseOUT™ and 200 units/^il of Superscript™ III Reverse Transcriptase 
were added to yield 20^il IX reaction mixture. The reaction was incubated for 1 
h at 50°C and was finally terminated by incubating at 70®C for 15 min. The 
resulting first-strand cDNA was directly subjected to conventional polymerase 
chain reaction (PCR) or real-time PCR amplification for the investigation of 
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specific gene expression. 
2.3.3 Design of primers for PCR and real-time PCR 
PCR primers for different genes were designed from human cDNA sequence 
using online software Primer 3 version 0.4.0 (Rozen and Skaletsky, 2000). 
Procedures were done according to the description by the software. Briefly, 
primers for each gene target were selected containing minimal internal structure 
(i.e. hairpins and primer-dimers formation as determined by the software) and 
having compatible primer size (Optimum: 20 ±3 b.p. of each complimentary 
pairs), optimal melting temperature (Optimum: 60 ±3°C of the other), and 
optimal GC content (Optimum: 50 ±20% of the other). Product size ranging 
from 50-200 base-pairs (b.p.) of each target gene was picked. Details of the 
sequence of the primers are shownwere depicted in Table 2.1. Each primer was 
tested by conventional PCR (procedure described in section 2.3.4) using positive 
cDNA as template. Only those primers which generate a single band ofexpected 
product size were used for further experiment. Besides, a cDNA dilution curve 
with at least 10 serial 2-fold dilutions was obtained from appropriate real-time 
PCR experiments (Procedures described in 2.3.5) and the PCR efficiency for 
each primer was evaluated. 
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Location Expected 
Gene Accession No. Primer sequence 
(nucleotides) size (bp) 
• . , . . • . . __^_^^^^^^_^___^^^^^__^_^__^^_^^^^^^^^^^^^^^^^^^^^^g^^^^^^^^^^^^^^^^^^^^^g^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^___^_^^^^^^^^aa^aB 
MHC-II 5'-GGACAAAGCCAACCTGGAAA-3'(sense) 351-370 
NM 019111.3 120 
(HLA-DRA) - 5'-AGGACGTTGGGCTCTCTCAG-3'(antisense) 470-451 
5'-AGGGAACATCACCATCCAAG-3'(sense) 235-254 
CD80 NM 005191.3 181 
- 5'-TGCCAGTAGATGCGAGTTTG-3'(antisense) 415-434 
5'-AGCTTTGCTTCTCTGCTGCT-3 ‘ (sense) 22-41 
CD86 NM 006889.3 142 
- 5'-ATCCAAGGAATGTGGTCTGG-3 '(antisense) 163-182 
5'-CCTGGACTCACACGGAAACT-3 '(sense) 29-48 
HLA-G NM 002127 64 
- 5'-AACCTGTCACCTAATGGGAGTG-3'(antisense) 92-113 
5'-CAGATGCTGGCACCTACAAA-3，(sense) 444-463 
B7H4 NM 024626.2 130 
- 5'-AAGGTCTCTGAGCTGGCATT-3'(antisense) 573-592 
Table 2.1 Primers-pairs designed and used for the study of immuno-related gene 
expression in PPCs and ICCs 
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2.3.4 Polymerase chain reaction (PCR) 
The first strand cDNA was subjected to PCR reaction. Oligonucleotide primers 
and expected PCR product sizes which were cited in the literature are 
summarized in Table 2.2 (Invitrogen). PCR was performed in 25^il reaction 
volume containing 5 i^l template cDNA, 1.5 mM MgCl2, 0.2 mM dNTP mix, 0.3 
^iM each of sense and anti-sense primer, PCR buffer and Taq DNA polymerase 
(Invitrogen). The reaction was initiated at 94�C for 3 min for denaturation, then 
annealing at temperature ranging from 60-64�C for the gene of interest, and 
finally extending at 72°C for 30 s. PCR cycles were repeated for 34 cycles. PCR 
products were then electrophoresed on a 2% agarose gel (wt/vol; Cambrex 
Corporation, Charles City, IA, USA) in IX Tris-Acetate-EDTA (TAE) buffer 
pre-stained with ethidium bromide for 15 min at 100V and the resulting bands 
were visualized using a camera equipped with an UV illuminator (FluroChem 
8000 Advanced Fluorescence, Chemiluminescence and Visible Light Imaging, 
Alpha Innotech Corporation, CA，USA) 
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Expected 







5'-CCAGGCGGCTTTATTGGTAGC-3，(antisense) Brands et 






5 '-TGGCACCACACCTTCTACAATGAGC-3'(sense) Huang et 
R-actin 396 
5'-GCACAGCTTCTCCTTAATGTCACGC-3 '(antisense) al., 2003 
P-actin 5'-TGTCCACCTTCCAGCAGATGT-3'(sense) 51 Suen et 
(Real-time) 5'-CGGACTCGTCATACTCCTGCTT-3'(antisense) al., 2006 
Table 2.2 Primer-pairs used for the study of immuno-related gene expression in PPCs and 
ICCs 
84 
CHAPTER 2 MATERIALS AND METHODS 
2.3.5 Real-time PCR analysis 
Real-time PCR were performed using i-Cycler Thermal Cycler (version 3.1; 
Bio-Rad Laboratories Incorporation, Munich, Germany) as previously described 
(Leung et al.，2009), with the following conditions: 40 cycles of 94¾ for 15s, 
60-62�C for 1 min depending on the gene of interest, and 72�C for 30s. 
Reactions were performed in triplicate, in 25 ^il, with 5^il 5-fold diluted cDNA, 
SYBR Green PCR Master mix (Bio-Rad Laboratories Incorporation) and 0.3 
^iM each primers (Invitrogen). Melting curve (+ 0.5�C for every 10 s) analysis 
was performed to confirm amplification specificity of the PCR products. 
Amplification data was collected using an i-Cycler Detector and analyzed using 
the Sequence Detection System Software. Results are normalized to p_actin and 
the relative mRNA level of the gene of interest is expressed as 1七似(Livak and 
Schmittgen, 2001). The schematic diagram of real-time PCR using SYBR Green 
assay is shown in Figure 2.2. 
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Figure 2.2 The principle of SYBR Green detection in real-time PCR. (1-2) The 
fluorescent dye SYBR Green is added to the mixture of PCR. SYBR Green is a DNA 
dye that bounds only to double-stranded DNA and it emits fluorescence upon 
• excitation. (3) At the beginning of the reaction light emission is low since little 
double-stranded DNA is present. (4) As the reaction proceeds, the amount of 
double-stranded DNA increases and hence emission of fluorescence increases. (5)Ci 
value is calculated based on the time at which fluorescent emission increases beyond a 
threshold level. (6) The denaturation steps contain only single-stranded DNA and 
signal is only detected during annealing and extension. [Picture extracted from: 
Diagnostic Procedures/ Stool Specimens/ Molecular diagnosis 
"http://www. dpd. cdc.gov/dpdx/html/frames/diagnostic procedures/hody_dp_stool_rt 
pcrJllust.htm” on 07June2010] 
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2.3.6 Calculation using the comparative Cj method 
The fold changes in the target genes mRNA expression were calculated using 
the 2_AACT method (Suen et al., 2008). SYBR Green is a dye that binds the minor 
groove of double-stranded DNA and emits fluorescence upon excitation. In 
Real-time PCR, C j value is calculated based on the time at which fluorescent 
emission increases beyond a threshold level. The fluorescent intensity correlates 
to the level oftarget mRNA; a greater quantity of input mRNA results in a lower 
Cx value since less PCR cycles are required for the fluorescent emission beyond 
the threshold. The ACx value of a target gene is calculated by subtracting the Ci 
derived from the house-keeping gnen p_actin. The AACx value is the differential 
gene expression of two samples which is calculated by subtraction ofthe control 
ACx from ACx of according samples. The expression level of the respective 
target gene relative to the control ACx is calculated using the equation 2'^^^^. 
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2.4 Flow cytometry 
The basic principle of flow cytometry is illustrated in Figure 2.3. PPC and ICCs 
treated with PBS control or 200U/ml IFN-y for 48 hr were harvested and collected by 
centrifugation. ICCs were segregated into single cells by using 0.05% trypsin 
(Invitrogen) for 15 mins followed by gentle pipetting. Cells at concentration l><10^ 
cell/ml were resuspended in ice-cold staining buffer (IX PBS supplemented with 1% 
FBS). Suspended cells were blocked with normal donkey serum in ice-cold staining 
buffer on ice for 30 min. They were then incubated with 20 i^l FITC-conjugated mouse 
anti-Human HLA-A,B,C antibody (BD Biosciences) on ice for 30 min. Cells were 
then washed by cold staining buffer for three times and reconstituted in 700^il cold 
staining buffer for cytometric analysis. Isotype control samples were incubated with 20 
|j,l FITC-conjugated mouse IgGlK isotype antibody (BD Biosciences). Cytometric 
analysis was performed by a CytomicsTM FC500 flow cytometer (Beckman Coulter, 
Fullerton, CA). 
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Figure 2.3 The basic principle of flow cytometry and two classical data output formats. 
(Left-hand side) Cells are labeled with one or more types of fluorescent antibodies. The 
sample in sheath fluid is hydrodynamically focused to pass through a laser-detector system 
in which the fluorescent character of each cell is measured. (Right-top) One dimensional 
histogram showed a single parameter of fluorescence on the x-axis and the number of 
events (cell count) on y-axis. (Right bottom) Two dimensional dot plot displays two 
measurement parameters, one on x-axis and one on y-axis, while the cell count is shown 
as a density plot. The parameters can be relative fluorescence or light scatter intensity. 
[Extracted and modified from http://www. microvet. arizona. edu/courses/VSC519/ 
Secure/CaseNoIg/Case4NoIg. html on 7June2010J 
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2.5 Western blot analysis 
2.5.1 Protein extraction and quantification 
Cell lysates from PPCs and JEG-3 were prepared using Cytobuster Protein 
Extraction Reagent O^ovagen, Darmstadt, Germany). The mixtures were 
incubated at room temperature for 15 min and centrifuged at 16,000 g at 4°C for 
15 min. Protein concentration was quantified using the Bio-Rad protein assay kit 
(Bio-Rad Laboratories Incorporation), which based on the method of Bradford. 
Protein samples were incubated with an acidic dye for 8 min at room 
temperature before measuring the absorbance at 595 nm with a spectrometer 
(Version 1.3, KCjunior, Bio-tek Instrument Inc., VT, USA). The relative 
determination of protein concentration was interpolated with the 0.1-0.5 mg/ml 
BSA standard curve. 
2.5.2 Western blotting 
Western blotting procedures were performed as previously reported with minor 
modifications (Leung et al., 2009). Briefly, protein samples were mixed with 
Laemmli buffer containing 5% P-mercaptoethanol. They were heat-denatured at 
100^C for 5 min. Denatured protein samples (15-30 ^ig/lane) were subjected to 
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electrophoresis on a 12% SDS-polyacrylaminde gel at 100V for 2 h. Proteins 
were then immobilized on 0.45 micron polyvinylidene difluoride (PVDF) 
transfer membrane (GE Osmonics Labstore, Minnetonka, MN, USA). 
Electroblotting was conducted by Semi-Dry Transfer System (Bio-Rad 
Laboratories Incorporation) at 17 volts for 1 h. The blotted protein was blocked 
in 5% (wt/vol) of skimmed milk in PBS and 0.1% (vol/vol) ofTween 20 for 1 h 
at room temperature. The membrane was subsequently incubated in primary 
antibodies including mouse anti-HLA-G (1:250; EBioscience, San Diego, Calif., 
USA) and mouse anti-p-actin (1:8000; Abcam，Cambridge, MA) overnight at 
4°C, followed by peroidase-labelled sheep anti-mouse IgG antibody (1:2500; 
Amersham Biosciences, Buckinghamshire, UK) for 1 h at room temperature. All 
antibodies were diluted in 1% BSA (wt/vol) supplemented with 0.5% (vol/vol) 
Tween-20 (Sigma-Aldrich). After thorough washing, positive bands were 
visualized using enhanced chemiluminescent (ECL) plus Westem blot detection 
reagents and autoradigraphy film (Amersham Biosciences). The 
chemiluminescent intensity of the protein bands was quantified using an image 
analyzer (Molecular Dynamic Imaging Quant, Sunnyvale, CA, USA). 
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2.6 Mixed lymphocyte reaction (MLR) 
2.6.1 Isolation ofperipheral blood mononuclear cells (PBMC) 
Human fresh blood or DMSO frozen blood samples were kindly provided by Dr. 
K.S. Tsang (Department ofAnatomical and Cellular Pathology, CUHK). PBMCs 
isolation procedures were performed as previously reported with minor 
modifications (Boyum 1968; Bain & Pyshyk, 1972; Jin et al., 1987) The PBMCs 
isolation process was depicted in figure 2.4. Blood samples were diluted at a 
ratio o f l : 2 0 by ice-cold PBS supplemented with 10% FBS. The vials were then 
centrifuged at 400 g for 10 min at room temperature. For frozen blood samples 
the pellet was washed once by ice-cold 10% FBS/PBS to remove DMSO. Cell 
pellets were then resuspended in 10% FBS/PBS. The cell suspension was 
overlaid on Ficoll-Paque™ Premium (Amersham Biosciences) of specific 
density of 1.077 and PBMCs can be isolated by centrifugating at 400 g for 30 
min at room temperature with brake off. The upper plasma layer was removed 
till 5 mm above the interface of Ficoll Hypaque portion and PBMCs were 
collected at mononuclear cell layer at the plasma-ficoll interface. A volume of 
the density gradient until 5 mm above red blood cell layer were also harvested to 
increase the yield. The yield was washed twice with ice-cold 10% FBS/PBS to 
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remove ficoll. The cell pellet was resuspended with modified RPMI 1640 
medium and the cell number was adjusted to 2xl0^ cell/ml in a T75 cell culture 
flask. The cells were incubated at 3TC in a humidified 5%-CO2-incubator for 
1-2 h to allow the adherence of monocytes to culture surface. The flask was 
rocked gently and monocyte-depleted lymphocytes were aspirated to another 
T75 flask. Viable lymphocytes were cultured for a couple of days. Cell viability 
was confirmed under light microscope by 0.5% trypan blue, based on the 
rationale that viable cells were able to exclude the dye whereas non-viable cells 
were stained blue. Cell viability was calculated as follows: 
Total number of unstained cells counted 
Cell viability (%) = xiOQo/o 
Total number of cells counted 
Only samples with the viability over 90% would be used in this study. 
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Figure 2.4 Schematic diagram of human peripheral blood mononuclear cells (PBMCs) 
isolation by ficoll gradient. Diluted blood is overlaid on Ficoll of specific density o f l .077 
and PBMCs can be isolated by centrifugating at 400 g for 30 min at room temperature 
with brake off. PBMCs were collected at mononuclear cell layer at the plasma-ficoll 
interface. Red blood cells are at the bottom of the tube. The yield was washed twice with 
ice-cold 10% FBS/PBS to remove ficoll. Cell pellet was resuspended with modified RPMI 
1640 medium in a T75 cell culture flask. The cells were incubated for 1-2 h to allow the 
adherence of monocytes to culture surface. The flask was rocked gently and 
monocyte-depleted lymphocytes were aspirated to another T75 flask. 
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2.6.2 PPC-PBMC MLR 
Cell number-dependent unidirectional (one-way) MLR were performed by 
co-culturing isolated PBMCs (2xl0^ cells/well) with irradiated PPCs (1500 rad) 
at different cell numbers (lxlO^ lxlO^ lxlO^ 5xlO^ lxlO^ cells/well) in a 
96-well plate (Coming Incorporated). MLR for comparing first- and 
second-trimester PPCs were performed by co-culturing PBMCs (2xl0^ 
cells/well) with irradiated PPCs (5xlO^ cells/well). Allogenic control was 
performed by co-culturing PBMCs with mismatched irradiated PBMCs (3000 
rad) as previously reportedChong et al., 1990), of each 2xl0^ cells/well. For all 
experimental setup the modified RPMI 1640 medium for PPCs as described in 
section 2.12 was used in MLR. The MLR was cultured for 6 days for 
proliferation assay (refer to Section 2.5.4) or 3 days for cytokine assay (refer to 
Section 2.8). 
2.6.3 ICC-PBMC MLR 
MLR were performed by co-culturing isolated PBMCs (2X10^ cells/well) with 
approximately 50 irradiated ICCs (1500 rad) in ultralow 24-well plate (Coming 
Incorporated). The modified RPMI 1640 medium for ICCs were used in MLR. 
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The MLR was cultured for 6 days for proliferation assay (refer to Section 2.5.4). 
2.6.4 Proliferation assay 
Cell proliferation Biotrak™ ELISA System (version 2; GE Healthcare, Orasy, 
France) was employed to assay PBMC proliferation. Cell proliferation was 
evaluated based on the measurement of 5 -bromo-2 ‘ -deoxyuridine (BrdU) 
incorporation during DNA synthesis in proliferating cells. The technique makes 
use of the incorporation of the pyrimidine analogue BrdU instead of thymidine 
into the DNA of proliferating cells. BrdU is detected by immunoassay. The 
procedures were performed according to manufacturer's instructions. Briefly, 18 
h before the PPCs/ICCs and PBMCs have been co-cultured for 6 days, lOmM 
BrdU labeling solution were added to the culture and incubated at 37°C. For 
PPC-PBMC MLR, medium with the labeling solution were removed on day 6. 
For ICC-PBMC MLR, ICCs were filtered from the medium through a nylon net 
>^ 
filter of pore size 160um (Millipore Corporation, Bedford, MA) carried by 
• 
• 13mm Swinnex® Filter Holder (Millipore). The remaining filtrate containing 
$• 
&:•�. 
medium and PBMCs were plated into a 96-well plate and spun at 400 g in a 
r r . 
[. microplate centrifuge. Plates were air-dried at 60®C for 1 h. The cells were fixed 
E: i ‘ 
i/ 
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and then blocked for 30 min each at room temperature. A peroxidase-conjugated 
mouse monoclonal anti-BrdU antibody was added and incubated for 90 min at 
room temperature. After three washes, BrdU was visualized by adding the 
substrate reaction. The absorbance of each well was measured at 450 nm using 





[ ; . • 
-
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2.6.2 PPC-PBMC MLR 
Cell number dependent unidirectional (one-way) MLR were performed by 
co-culturing isolated PBMCs (2xl0^ cells/well) with irradiated PPCs (1500 rad) 
at different cell numbers (lxlO^ l><10^ lxlO^ 5xlO^ l><10^ cells/well) in a 
96-well plate (Coming Incorporated). MLR for comparing first- and 
second-trimester PPCs were performed by co-culturing same number of PBMCs 
with irradiated PPCs cell numbers of 5xlO^ cells/well. Allogenic control was 
performed by co-culturing PBMCs with mismatched irradiated PBMCs (3000 
rad) as previously reported(Chong et al.，1990), of each 2xl0^ cells/well. For all 
experimental setup the modified RPMI 1640 medium for PPCs as described in 
2.12 were used in MLR. The MLR was cultured for 6 days for proliferation 
assay (refer to section 2.5.4) or 3 days for medium cytokine level assay (refer to 
Section 2.8). 
.. • 
2.6.3 ICC-PBMC MLR 
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f MLR were performed by co-culturing isolated PBMCs (2X10^ cells/well) with 
approximately 50 irradiated ICCs (1500 rad) in ultralow 24-well plate (Coming 
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2.7.2 Procedures ofICC transplantation 
The methodology for ICCs transplantation which has been described previously 
was used in this study (Suen et al., 2006). The procedures of transplantation are 
illustrated in Figure 2.5. Atotal o f22 animals was operated. Briefly, 1,000-1,500 
ICCs of similar size derived from the first and second trimester after 8 days of 
differentiation were picked under the microscope. The differentiation medium 
was removed from the selected ICCs by centrifugation and ICCs were 
resuspended in a small volume of sterilized 0.9% (wt/vol) saline. ICCs were 
then carefully packed into the tip of MICROMAN® positive displacement 
pipette (Gilson, Middleton, Wisconsin). STZ-treated C57BL/6J mouse was 
anesthetized with an intraperitoneal injection of 1% (vol/vol) ketamine (Alfasan, 
Woerden, Holland) and 0.1% (vol/vol) xylaxin (Alfasan). The left abdomen of 
the mouse was cut opened. The left kidney was exposed and kept moisturized by 
0.9% sterilized saline. A small incision was made on the left renal capsule. ICCs 
were gently introduced between the renal parenchyma and the capsule by using 
a displacement pipette, followed by suturing of the skin opening. Sham-operated 
mice were injected with 0.9% sterilized saline. Blood glucose levels of the 
transplanted mice were monitored for two weeks. Blood was withdrawn from 
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tail snip and blood glucose level was assessed using a handheld glucometer 
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Figure 2.5 Islet-like cell clusters transplantation to C57BL/6J mice. (A) The left abdomen 
of an anesthetized C57BL/6J mice was cut opened and left kidney was exposed. A small 
incision was then made on the left kidney capsule. (B) ICCs were gently introduced 
between the renal parenchyma and the capsule by the displacement pipette. (C) The 
transplanted ICCs graft was visible within the renal capsule as indicated by the white 
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2.8 Histological analysis ofICC graft 
H&E staining and immunohistochemistry were performed according to our previously 
reported with some minor modifications (Suen et al., 2006) 
2.8.1 H&Estaining 
Grafted kidneys were fixed in 4% (wt/vol) paraformaldehyde (PFA;Sigma 
Aldrich) in PBS at 4^C for 48 h. Fixed grafts were washed twice by PBS and 
then subjected to sucrose gradients as follows: 10% sucrose/PBS for 12h; 20% 
sucrose/PBS for 24h; 30% sucrose/PBS for 24h. They were then embedded in 
Tissue-Tek@ O.G.T. Compound (Optimal Cutting Temperature Compound; 
Sakura Finetek, Torrance, CA, USA) and were frozen in -80°C overnight. 
Embedded kidneys were sectioned at 5-6 i^m by LEICA CM1100 Benchtop 
Cryostat (Leica Microsystems) and were mounted onto silane-coated slides. 
These slides were air dried at room temperature for few hours and the O.C.T. 
(Sakura) was removed from the sections by rinsing in PBS twice prior to 
staining process. Sections were stained with hematoxylin for 5-8 min to 
visualize the nucleus. The intensity of hematoxylin was optimally adjusted by 
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counter-Stained with 1% eosin for 5 min to visualize the cytoplasm. The slides 
were de-hydrated by passing through a sequential gradient of ethanol (70% to 
absolute ethanol, each for 30s) and xylene (three times, each for 30s), and then 
eventually mounted by the microscopic Entellan® rapid-mounting media 
(Merck, Germany). Histological changes were examined under a light 
microscope equipped with a DC200 digital camera (Leica Microsystem). 
2.8.2 DAB staining 
For the immunostaining ofFDX-J, sections were incubated with 3% hydrogen 
peroxide in PBS for 10 min to denature endogenous peroxidase activity and 
were washed in PBS for three times. They were then permeabilized with 0.1% 
Tritox-X in PBS for 10 min and washed. Blocking of non-specificity was done 
by incubating sections with 4% normal donkey semm (Sigma) in 1:20 (vol/vol) 
Tris Buffered Saline & Tween 20 (TBS-T; Thermo Scientific, Waltham, MA) 
supplemented with 2% bovine semm albumin (BSA; Invitrogen) at room 
temperature for 1 h. Rabbit anti-FDX-J antibody (Millipore) with dilution 1:200 
were applies to slides and incubated at 4°C overnight. They were washed with 
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with HRP (Amersham Biosciences) at dilution of 1:200 for 1 h at room 
temperature. Slides were washed and developed with 3,3-diaminobenzidine 
(DAB; Vector Laboratories, CA, USA) for 5 min. After washing, sections were 
dehydrated and mounted as described above. The omission of primary 
antibodies was used as negative controls. 
2.8.3 Immunofluorescence staining of CD45 
Immunofluorescence staining of CD45 was performed as previously described 
(Leung et al., 2009). Briefly，samples were blocked with 4% normal donkey 
serum in TBS-T supplemented with 2% bovine serum albumin (BSA) at room 
temperature for 1 h. They were then incubated with rat anti-CD45 antibody 
(1:10; BD Biosciences) ovemight at 4 °C. Slides were washed three times with 
TBS-T and were then incubated with Rhodamine-conjugated goat anti-rat (1:200) 
secondary antibodies (Abcam) together with 4 ‘ 6 ‘ -Diamidino-2-phenylindole 
(DAPI; 1:1000; Invitrogen) at room temperature for 1 h. Sections stained with 
secondary antibody alone were used as negative control. All sections were 
washed thoroughly with TBS-T, mounted in Vectashield® Mounting Medium 
(Vector Laboratories Inc., Burlingame, CA，USA) and imaged using a 
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fluorescence microscope and DC 200 digital camera (Leica Microsystem). 
2.9 Enzyme-linked immunosorbent assay 
The IFN-y and IL-10 levels in the fresh and spent media were assayed qualitatively 
with Quantikine® Human IFN-y ELISA kit and Human IL-10 ELISA kit, respectively 
(R&D Systems). In brief, irradiated PPCs were seeded at 5xlO^ cells/well in 96-well 
plates and co-cultured with 2xl0^ PBMCs in the presence of 5mg/ml PHA-P (Sigma). 
Spent media were collected on day 3 cultures after removal of particulates by 
centrifugation at 300g. Assays were done immediately. Otherwise, they were aliquoted 
and stored at -80�C until analysis. Repeated freeze-thaw procedures were avoided for 
each frozen sample. In accordance with the manufacturers' instructions, the media 
were diluted using the assay diluent in the 96 well plate coated with polyclonal 
antibody against IFN-y or IL-10 and were incubated for 2 h. The mixtures were 
removed and washed 4 times. IFN-y- or IL-10-conjugated polyclonal antibodies were 
added to each well and incubated for 2 h. Substrate solution was added to each well 
after washing for 4 times and incubating for 30 min in dark. Stop solution was added 
to each well and the optical density was determined within 30 min using the 
spectrometer (Version 1.3, KCjunior) at 450 nm, with the wavelength correction at 540 
nm. Actual concentrations were obtained from the curve of mean absorbance with 
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Standardized 0-500 pg/ml IFN-y or IL-10 controls. 
2.10 Statistical data analysis 
Results were expressed as mean 土 SEM for all groups. Multiple comparisons among 
groups were performed using an ANOVA followed by Tukey's post hoc test. When 
only two groups were compared, probabilities (p value) of chance differences were 
calculated with Student's unpaired two-tailed t test. Graphical and statistical analyses 
were conducted using a GraphPad Prism 5 software package (GraphPad Software Inc., 
San Diego, CA). For all comparisons, p<0.05 was considered statistically significant. 
For real-time RT-PCR, the relative expression was normalized to P-ACTIN and 
calculated using the comparative Cx method, with fold change defined as 2'^^^^, as 
described previously (Lau et al., 2004). 
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3.1Immuno-characterization of PPCs and ICCs 
To characterized the immunologic nature of our PPCs and ICCs, the mRNA expression of 
some selective immune-related genes, including HLA-A, MHC-II, complement 
component 3 (C3), chemokine ligand (CCL19), tumor necrosis factor super family 
(TNFSF10), innate molecules (B7H4), co-stimulatory molecules, CD80 and CD86, along 
with non classical MHC-I molecule HLA-G were evaluated by semi-quantitative RT-PCR 
(Figure 3.1). Results showed that all genes, except for co-stimulatory molecules, CD80 
and CD86, were expressed by both PPCs and ICCs. The expression of MHC-I and 
MHC-II molecules by PPCs and ICCs suggested that they were able to present antigens to 
host T-cells for activation,thus triggering immune response. The existence of these 
molecules lends support to the equipped antigen presenting machinery of PPCs and ICCs. 
Conversely, the absence ofco-stimulatory molecules, CD80 and CD86, is indicative ofthe 
immuno-privileged status of these cells. Of particular interest is the expression of the 
non-classical MHC class I molecule HLA-G by both PPCs and ICCs. 
To compare the immunogenicity of PPCs with fetal pancreas (Figure 3.2), the mRNA 
expression of MHC-I derived from these samples were further examined by quantitative 
real-time PCR. Result showed that the expression of MHC-I on a 12 week fetal pancreas 
(2_AACT; 2.93i0.225) was 3-fold higher thanthat of the isolated PPCs of the same week. 
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Figure 3.1 The mRNA expression of some selected immune-related genes from PPCs and 
ICCs. Expression of HLA-A, MHC-II, complement component 3 (C3), chemokine ligand 
(CCL19), tumor necrosis factor super family (TNFSF10), innate molecules (B7H4), 
costimulatory molecules CD80 and CD86 as well as HLA-G are evaluated by RT-PCR. 
Human p-actin is used as an internal control while another three positive controls are 
employed, i.e. (a) fetal kidney; (b) HSCs; (c) JEG-3. 
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Figure 3.2 Real-time RT-PCR analysis of the mRNA expression of MHC-I molecules 
from PPCs and human fetal pancreas. MHC-I expression by fetal pancreas is 3-fold higher 
than that of PPCs. The relative expression is normalized as percentage of P-actin 
calculated using the comparative Ci method of 2'^^^^. All data are expressed as means 
±SEM for three experiments in each group, ***denotes p<0.001 when compared to PPC 
control. 
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3.2Effect ofcytokines on immuno-properties of PPCs/ICCs 
3.2.1 Effect of IFN-y on MHC-I expression in PPCs 
To investigate the effect of IFN-y on MHC-I expression, PPCs were cultured with 
100, 200 and 500U/mL of human recombinant IFN-y for 2 and 4 days. Quantitative 
real-time PCR results revealed that the expression of MHC-I molecules in the PPCs 
was dose-dependently and time-dependently upregulated by IFN-y (Figure 3.3). In 
this regard, IFN-y of dosage 200U/mL for 2 and 4 days (11.08士0.499 vs 14.73士1.45 
respectively) induced an increase in MHC-I expression of more than 10 folds, and the 
fold change accounted for >20 folds when they were cultured with 500U/mL for 4 
days (22.27il.91). In the subsequent experiments we employed 200U/mL IFN-y for 
2 days in the following experiments as widely employed in other studies 
(Kirchheimer et al., 1988; Ljunggren & Anderson, 1998; Conte et al., 2003; Wen et 
al., 2004;). 
The induction of expressions of MHC-I molecules by IFN-y on the PPCs was also 
examined by flow cytometry (Figure 3.4). Data revealed that 100% of untreated 
PPCs were detected positive against surface MHC-I expression and obvious shift of 
peak was observed in PPCs treated with IFN- y, indicating that the average 
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expression of MHC-I molecules on cell surface was increased after incubation with 
IFN- Y. These experimental data demonstrated that PPCs were subjected to MHC-I 
induction by IFN- y. 
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Figure 3.3 Real-time RT-PCR analyses of the mRNA expression of MHC-I molecules in 
IFN- Y treated PPCs. PPCs were cultured with 100, 200 and 500U/mL human recombinant 
IFN-y for 2 and 4 days. The expression of MHC-I molecules in PPCs was significantly 
upregulated by IFN-y at different concentrations (lOOU/mL, 200U/ml and 500U/mL) for 
different days (2 and 4 days). The relative expression was normalized as a percentage of 
P-actin calculated using the comparative Ci method of 2"^^^^. All data were expressed as 
means ±SEM for three experiments in each group.*denotes p<0.05 when compared to 
4-days control; ### and *** denote p<0.001 when compared to 2-days and 4-days control, 
respectively. 
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Figure 3.4 A representative histogram of the flow cytometric analysis of surface MHC-I 
expression in IFN-y untreated and treated PPCs. PPCs were cultured with 200U/mL 
human recombinant IFN-y for 2 days before flow cytometry analysis. The fluorescent 
intensity of MHC-I detection increase after pre-treatment of IFN-y, suggesting an 
upregulation ofMHC-I molecules on cell surface. The non-specific binding is normalized 
by the use of isotype antibody. Yellow: isotype control; Red: PPCs control; Blue: PPCs 
treated with 200U/mL IFN-y for 48hr. 
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3.2.2 Effect ofIFN-y and IL-10 on HLA-G expression in PPCs and ICCs 
The effect of IL-10 on HLA-G expression in PPCs and ICCs was evaluated by 
quantitative real-time PCR. PPCs and ICCs were incubated with 5, 25 and lOOU/mL 
human recombinant IL-10 for 2 days. Results revealed that IL-10 upregulated 
HLA-G expression on PPCs (Figure 3.5) and ICCs (Figure 3.6), peaking at 25U/mL 
(5.99il.39 and 3.18±0.07)，respectively. Data implies the capacity of IL-10 on 
HLA-G induction in PPCs/ICCs. Western blot analyses were employed to investigate 
the effect ofIFN- y and IL-10 on the protein expression ofHLA-G. Aprevious report 
demonstrated a predominant expression of HLA-G by the human placental 
choriocarcinoma cell line JEG-3 (Yie et al., 2006). Therefore, it was employed as 
positive control for HLA-G expression. JEG-3 cell line and PPCs were pretreated 
with 25U/mL IL-10 or 200U/mL IFN-y for two days. Figure 3.7 revealed that 
HLA-G protein was upregulated in both PPCs and JEG-3 after IL-10 treatment, while 
the HLA-G protein remained unchanged in both PPCs and JEG-3 cells treated with 
IFN-y. 
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Figure 3.5 Real-time RT-PCR analyses of the mRNA expression of HLA-G on IL-10 
treated PPCs. PPCs were cultured with 5，25 and lOOU/mL human recombinant IL-10 for 
2 days. The expression of HLA-G gene was upregulated by IL-10, peaking at 
25U/mL. The relative expression was normalized as a percentage of P-actin calculated 
using the comparative Cx method of 2'^^^^. All data are expressed as means ±SEM for 
three experiments in each group.*denotes p<0.05 when compared to control; ** denotes 
p<0.01 when compared to control. 
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Figure 3.6 Real-time RT-PCR analysis of the mRNA expression of HLA-G on IL-10 
treated ICCs. ICCs were cultured with 5, 25 and lOOU/mL human recombinant IL-10 for 2 
days. The expression of HLA-G gene on ICCs was upregulated by IL-10, peaking at 
25U/mL. The relative expression was normalized as a percentage of P-actin calculated 
using the comparative Ci method of 2'^^^^. All data are expressed as means ±SEM for 
three experiments in each group.*denotes p<0.05 when compared to control; ** denotes 
p<0.01 when compared to control. 
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Figure 3.7 Westem blotting of the HLA-G protein in JEG-3 and PPCs treated with 
200U/mL IFN-y and 25U/mL IL-10 for 2 days. JEG-3 was employed as the positive 
control. (A) HLA-G protein derived from different treatments. 20 microgram aliquots of 
protein were loaded in each well. (B) The relative expressions of HLA-G by JEG-3 and 
PPCs after treatment with IFN-y or IL-10. HLA-G protein expression in PPCs is 
upregulated by IL-10, while unchanged by IFN- y. The relative expression was normalized 
as percentage of p_actin. 
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3.2.2 Effect of IFN-y on B7H4 expression in PPCs 
B7H4 is an innate molecule recently shown to be taking part in the 
immuno-modulation process (Prasad et al., 2003). The expression has been reported 
to be affected by certain cytokines (Sica et al., 2003). PPCs were incubated with 
IFN- Y of concentrations 100，200 and 500U/mL for 2 days for mRNA expression of 
B7H4. RT-PCR revealed a dose-dependent upregulation of immuno-suppressive 
B7H4 mRNA in PPCs by IFN- y (Figure 3.8). 
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Figure 3.8 RT-PCR for mRNA expression of B7H4 on IFN- y treated PPCs. PPCs were 
cultured with 100，200 and 500U/mL human recombinant IFN-y for 2 days. The 
expression ofB7H4 on PPCs increased dose-dependently by IFN-y. Fetal kidney was used 
as the positive control. RT-PCR for p-actin was used as housekeeping gene. 
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3.3Comparison of immuno-properties of PPCs and ICCs from 1'* and 2"^  
trimester 
A recent study demonstrated a reduction of immunogenicity in human fetal pancreas 
(Brands et al., 2008). In this study a lowered MHC-I expression in PPCs than in fetal 
pancreas was noted. In this regard the immune-properties of PPCs derived from first 
(9-11 wk) and early second trimester (12-14wk) was analyzed. 
3.3.1 Differential expression ofMHC molecules in PPCs 
The temporal expressions of MHC-I and II molecules in PPCs of different gestation 
weeks (9-14weeks) were evaluated by quantitative real-time PCR. Figure 3.8 
revealed that no significant change in MHC-I expression across 9^ ^ to 12^ ^ week, 
however MHC-I remarkably increased in PPCs at 13th (4.18i0.584) and 14th week 
(5.30il.21) when compared to that from 9^ week. 
Temporal expressions ofMHC-II were also examined. MHC-II gene was upregulated 
at lOth week PPCs (22.77±1.82) compared to that from 9出 week. The level continued 
to rise and peak at 12出 week (103士5.29). Results showed a remarkable increase in the 
mRNA expression ofMHC-II in PPCs derived from the second trimester. 
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Figure 3.9 Real-time RT-PCR for mRNA expression of MHC-I in 9th-14th week PPCs. 
MHC-I gene was significantly upregulated at 13^ ^ week and 14仇 week. The relative 
expression was normalized as a percentage of P-actin calculated using the comparative Ci 
method of 2'^^^^. All data are expressed as means ±SEM for three experiments in each 
group.*denotes p<0.05 when compared to 9 week PPCs; ** denotes p<0.01 when 
compared to 9 week. 
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Figure 3.10 Real-time RT-PCR for mRNA expression ofMHC-II in 9th-14th week PPCs. 
MHC-II gene was significantly upregulated 11出 week onward, peaking at 12出 week. The 
relative expression was normalized as a percentage of P-actin calculated using the 
comparative Cx method of ：么…丁. All data are expressed as means ±SEM for three 
experiments in each group. ** denotes p<0.01 when compared to 9 week PPCs; *** 
denotes p<0.001 when compared to 9 week. 
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3.3.2 Different immuno-related gene expression in PPCs and ICCs 
To further elucidate the immunological difference between PPCs and ICCs at 
different stage ofmaturation, the mRNA expressions of several selected immune 
related genes were evaluated by real-time PCR. The mRNA expressions of 
pro-inflammatory (Figure 3.11) molecules namely, MHC-I, MHC-II, TNFSF10 
and C3, were increased in PPCs at second trimester (MHC-I; 4.74士0.652， 
MHC-II; 91.3i7.87, TNFSF10; 104.8士19.5 and C3; 22.27±4.46). Among these 4 
pro-inflammatory molecules, MHC-II and TNFSF10 showed a more drastic 
increase than MHC-I and C3. On the other hand, the mRNA expression of 
immune-suppressing molecules B7H4 and HLA-G were downregulated (B7H4; 
0.02181士0.00519 and HLA-G; 0.486±0.0686) in PPCs of second trimester 
(Figure 3.12). Taken together, an upregulation of pro-inflammatory gene and 
down-regulation of immune-suppressive genes were noted in second trimester 
PPCs. 
Similar results were obtained in different ICCs. A higher mRNA expression of 
MHC-I, MHC-II, C3, TNFSF 10 (1.58±0.0535, 3.546i0.253, 2.354i0.355 and 
3.805士0.468 respectively) and lower level of B7H4 and HLA-G mRNA 
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(0.3187士0.0383 and 0.6512±0.1574 respectively) were detected in second 
trimester ICCs compared with those derived from first trimester(Figure 3.13 and 
3.14). Interestingly, the fold differences of gene expressions were much less in 
ICCs than in PPCs. 
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Figure 3.11 Real-time RT-PCR for mRNA expression ofMHC-I, MHC-II, TNFSF10 and 
C3 in PPCs offirst and early second trimester. The mRNA expression of pro-inflammatory 
molecules namely MHC-I, MHC-II, TNFSF10 and C3 were found significantly increased 
in PPCs of second trimester. The relative expression was normalized as a percentage of 
P-actin calculated using the comparative C j method of 2'^^^^. All data are expressed as 
means +SEM for three experiments in each group. *** denotes p<0.001 when compared 
to first trimester. 
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Figure 3.12 Real-time RT-PCR for mRNA expression of B7H4 and HLA-G in PPCs of 
first and early second trimester. The mRNA expressions of immune-suppressive molecules 
namely, B7H4 and HLA-G, were found significantly decreased in PPCs of second 
trimester. The relative expression was normalized as a percentage of P-actin calculated 
using the comparative Ci method of 2-么仏丁. All data are expressed as means ±SEM for 
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Figure 3.13 Real-time RT-PCR for mRNA expression ofMHC-I, MHC-II, TNFSFIO and 
C3 in ICCs of first and early second trimester. The mRNA expression of pro-inflammatory 
molecules namely, MHC-I, MHC-II, ·lNFSFIO and C3 were found significantly increased 
in ICCs of second trimester. The relative expression was normalized as a percentage of 
p':actin calculated using. the comparative CT method of 2-~~CT. All data are expressed as 
means +SEM for three experiments in each group. *** denotes p<O.OOl when compared 
to first trimester. 
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Figure 3.14 Real-time RT-PCR for mRNA expression of B7H4 and HLA-G in ICCs of 
first and early second trimester. The mRNA expression of immune-suppressive molecules 
namely, B7H4 and HLA-G, were found significantly decreased in ICCs of second trimester. 
The relative expression was normalized as a percentage of P-actin calculated using the 
comparative Ci method of 2_^ C^T All data are expressed as means ±SEM for three 
experiments in each group. * denotes p<0.05 when compared to first trimester; *** 
denotes p<0.001 when compared to first trimester. 
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3.3.3 Comparison ofIFN-y-activated MHC expression in PPCs and ICCs 
As shown in the study, the cytokine IFN-y was capable of inducing both the 
transcription and translation of MHC on PPCs and ICCs. It was unclear of any 
difference between the first and second trimester. Figure 3.15 and Figure 3.17 
show that IFN-y induced a significant higher MHC-I mRNA expression in 
second trimester PPCs and ICCs than in first trimester PPCs and ICCs 
(16.77i0.383 vs 21.12i0.482 in PPCs and 2.05±0.0924 vs 4.34士0.241 in ICCs). 
Besides, lower extent of MHC-I upregulation was noted in ICCs than PPCs. 
Flow cytometry analyses display a greater degree of right shift ofpositive signals 
in second trimester PPCs and ICCs than the first one in both PPCs (Figure 3.16) 
and ICCs (Figure 3.18), suggesting that IFN-y induced MHC-I transcription and 
translation in second-trimester PPCs and ICCs. 
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Figure 3.15 Real-time RT-PCR for mRNA expression of MHC-I in IFN-y induced PPCs 
of first and second trimester. Both groups showed an increased MHC-I expression after 
treatment of 200U/mL IFN-y for 2 days. The degree of upregualation in the gene 
expression of MHC-I was significantly higher in second trimester PPCs. The relative 
expression was normalized as a percentage of P-actin calculated using the comparative Cx 
method of 2'^^^^. All data are expressed as means ±SEM for three experiments in each 
group, ***denotes p<0.001 when compared to c o n t r o l ;漏 denotes p<0.001 when 
compared to IFN-y treatment in first trimester. 
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Figure 3.16 Flow cytometry analysis of surface MHC-I expression on IFN-y treated PPCs. 
Both PPCs of (A) first and (B) second trimester were treated with 200U/mL IFN-y for 2 
days. Yellow: isotype control; Red: PPC control; Blue: IFN-y treated PPC. Results 
revealed that a right shift of the signal intensity of MHC-I in treated PPCs. The shift of 
fluorescent intensity is more remarkable in second trimester PPCs. The non-specific 
binding is normalized by the used of isotype antibody. 
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Figure 3.17 Real-time RT-PCR for mRNA expression of MHC-I in IFN-y ICCs of first 
and second trimester. Both groups showed an increased MHC-I molecules expression after 
treatment of 200U/mL IFN-y for 2 days. The degree of upregualation in the gene 
expression ofMHC-I was significantly higher in second trimester. The relative expression 
was normalized as a percentage of P-actin calculated using the comparative C j method of 
2_AACT All data are expressed as means ±SEM for three experiments in each group, 
***denotes p<0.001 when compared to control; ### denotes p<0.001 when compared to 
IFN-y treatment in first trimester. 
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Figure 3.18 Flow cytometry analysis of surface MHC-I expression on IFN-y treated ICCs. 
Both ICCs of (A) first and (B) second trimester were treated with 200U/mL IFN-y for 2 
days. Yellow: isotype control; Red: PPC control; Blue: IFN-y treated PPC. Results 
revealed that a right shift o f the sgnal intensity of MHC-I molecules in treated ICCs. The 
shift of fluorescent intensity is more remarkable in second trimester ICCs. The 
non-specific binding is normalized by the used of isotype antibody. 
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3.3.4 Comparison of other IFN-y activated genes expression in PPCs 
Apart from MHC-I, the effect of IFN- y on gene expression of MHC-II, HLA-G 
and B7H4 in PPCs were also investigated. Surprisingly, after treatment with 
200U/mL IFN_ y for 2 days, the expression of MHC-II was drastically increased 
in PPCs (Figure 3.19), with over 50000 folds for first trimester (55340±17700) 
and over 150000 folds for second trimester (188900士27000). The data showed 
that IFN- y was a potent inducer ofMHC-II in PPCs. 
In contrast, the upregulation of mRNA expression of HLA-G and B7H4 by 
IFN- Y were not as drastic as MHC-II in PPCs. A two-fold increase in HLA-G 
mRNA expression was detected in PPCs of first trimester upon stimulation of 
IFN- Y, while no observable change was detected in second trimester (Figure 
3.20). IFN-y also mildly induced B7H4 mRNA expression in the first and 
second trimester PPCs, <2 folds in 1'^  trimester. The up-regulation ofHLA-G and 
B7H4 in PPCs by IFN- y suggested the potential immune-suppressive nature of 
PPCs upon cytokine challenges, which may help negatively regulate the immune 
response. 
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Figure 3.19 Real-time RT-PCR for mRNA expression ofMHC-II in IFN-y induced PPCs 
of first and second trimester. Both groups showed an increased MHC-I expression after 
treatment of200U/mL IFN-y for 2 days. The degree of upregulation in the gene expression 
of MHC-II was significantly higher in second trimester (>150,000 fold). The relative 
expression was normalized as a percentage of P-actin calculated using the comparative C j 
method of 2"^^^^. All data are expressed as means ±SEM for three experiments in each 
group, ***denotes p<0.001 when compared to control; ### denotes p<0.001 when 
compared to IFN-y treatment in first trimester. 
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Figure 3.20 Real-time RT-PCR for mRNA expression of HLA-G in IFN-y induced PPCs 
of first and second trimester. Both groups showed an increased MHC-I molecules 
expression after treatment of200U/mL IFN-y for 2 days. The degree of upregulation in the 
expression of MHC-I molecules was significantly higher in first trimester. The relative 
expression was normalized as a percentage of P-actin calculated using the comparative C j 
method of 2-么乂丁. All data are expressed as means ±SEM for three experiments in each 
group, ***denotes p<0.001 when compared to control; # denotes p<0.05 when compared 
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Figure 3.21 Real-time RT-PCR for mRNA expression ofB7H4 in IFN-y induced PPCs of 
first and second trimester. Both groups showed an increased B7H4 expression after 
treatment of 200U/mL IFN-y for 2 days. The relative expression was normalized as a 
percentage of p-actin calculated using the comparative C j method of 2"^^^^. All data are 
expressed as means ±SEM for three experiments in each group, **denotes p<0.01 when 
compared to control; *** denotes p<0.001 when compared to control. 
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3.4Mixed lymphocyte reaction ofPPCs from 1'* and 2"^  trimester 
3.4.1 Effect ofPPCs on proliferation ofPBMC 
The mixed lymphocyte reaction (MLR) is the in vitro assessment of the 
immunogenicity ofcells by co-culturing the target cells with the effector cells, and 
the proliferation of the target cells is assessed. The set-up has recently been used to 
evaluate the immunological status of different types of stem cells, such as MSCs, 
ESCs and neural stem cells as elsewhere reported. PPCs (5xlO^ 5><103, 5xlO^ and 
lxlO^ cells/well) were co-cultured with 2xl0^ isolated human PBMCs. BrdU 
incorporation assay revealed a significant increase in PBMC proliferation upon 
co-culture with PPCs at 5><10^  cells/well or above (Figure 3.22). Proliferation of 
PBMCs exhibited a peak at 5xlO^ cells/well PPCs (150±9.89%), and slightly 
dropped when the cell number reached lxlO^ (128.U6.23%). It would be 
attributed to the suboptimal culturing, which adversely effected the viability of 
PBMCs. In general, data showed that the cell number of PPCs present in the 
co-culture system correlated to the extent of proliferation of PBMCs, suggesting 
that PPCs could trigger the proliferation ofPBMCs. 
The MLR were then performed using PPCs of first and second trimester (Figure 
3.23). PPCs of different trimesters, either with or without cytokine pretreatment, 
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were co-cultured with PBMCs for 6 days. Irradiated PPCs showed minimal BrdU 
incorporation and pre-treatment of either IFN-y or IL-10 did not pose any 
significant effect on proliferation ofPPCs. The co-culture ofPBMCs with PPCs of 
both first and second trimester induced a significant PBMC proliferation, 
compared to PBMC alone. A higher extent ofBrdU incorporation was observed in 
co-cultures of PBMCs and PPCs of second trimester (120.6±7.83% vs 
140.6i3.79%). Early data of this study showed that IFN-y could upregulate the 
- MHC expression in PPCs. MLR results attested that IFN-y potentiated PPCs at the 
first and second trimesters inducing proliferation of PBMCs, via the upregulation 
o fMHC on PPCs. Similarly, the IFN-y-treated PPCs of second trimester elicited a 
more vigorous proliferation in PBMCs than first trimester PPCs (143.9±7.85% vs 
241.5i7.57%). 
PPCs of both trimesters were primed with IL-10 prior to MLR. Results revealed 
that the stimulatory effects of first trimester PPCs on PBMC proliferation were 
abolished with IL-10 (98.52±4.06%). However, the amelioration was not so 
obvious in second trimester PPCs (125.8±9.42%). To note, all the PPCs groups, 
irrespective of IFN-y and IL-10 treatment, exerted a lower proliferation on PBMCs, 
compared to the allogenic control (353.7±19.8%). 
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3.4.2 Effect ofICCs on proliferation ofPBMC 
Figure 3.24 displays the BrdU incorporation of PBMCs in co-culture of PBMCs 
with ICCs of second trimester. An enhanced BrdU incorporation was noted in 
co-cultures with and without IFN-y priming ofICCs (140.0±10.94%) 
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Figure 3.22 Brdu incorporation analyses of human PBMCs post mixed lymphocyte 
reaction. BrdU incorporation assay revealed a significant increase of BrdU incorporation 
in PBMCs upon the co-culture with PPCs at 5X10^ cells/well or above. The proliferation 
of PBMCs increased with the increase of PPCs (5X10^- 5X10^), and peaked at 5X10^ 
cells/well. The relative expression was normalized as a percentage of control. All data are 
expressed as means ±SEM for six experiments in each group, **denotes p<0.005 when 
compared to PBMC alone; ***denotes p<0.001 when compared to PBMC alone; ## 
denotes p<0.005 when compared to the lowest cell number. 
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Figure 3.23 Brdu incorporation analyses of human PBMCs post mixed lymphocyte 
reaction. BrdU incorporation assay revealed an increased proliferation of PBMC when 
co-culturing with PPCs of second trimester. The extent of proliferation of PBMCs were 
much higher when PPCs were pretreated with 200U/mL IFN- y for 2 days. The addition of 
IL-10 to PPCs tended to abolish the stimulative effect of first trimester PPCs of first 
trimester, however no evidence on second trimester PPCs. The degree of proliferation of 
PBMCs elicited by PPCs of all groups were lower than allogenic control. The relative 
expression was normalized as a percentage of the PBMCs control. All data are expressed 
as means ±SEM for six experiments in each group, *denotes p<0.05 when compared to 
PBMC alone; ***denotes p<0.001 when compared to PBMC alone; # denotes p<0.05 
when compared to according PPC of first trimester; ## denotes p<0.005 when compared 
to according PPC of first trimester. 
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Figure 3.24 BrdU incorporation analyses of human PBMCs post mixed lymphocyte 
reaction. BrdU incorporation assay revealed an increased proliferation of PBMC when 
co-culturing with ICCs of second trimester (n=2). The degree of proliferation of PBMCs 
were more remarkable when ICCs were pretreated with 200U/mL IFN- y for 2 days. The 
relative expression was normalized as percentage of the according control. 
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3.4.3 Effect ofPPCs on Cytokines production in PBMC 
MLR were also performed in the presence of lymphocyte stimulating factor, 
PHA-P, to investigate the cytokine release profile upon co-culture with PPCs at the 
first and second trimesters. ELISA showed a basal release of IFN- y (3024±76.0 
pg/mL) from PBMCs when stimulated with PHA-P (Figure 3.25). There was a 
significant surge of IFN- y in co-cultures of PHA-P stimulated PBMCs and PPCs 
at the first and second trimester (3493±251 pg/mL for first trimester vs 5642±130 
pg/mL for second trimester). 
The level of IL-10 was also evaluated (Figure 3.26). ELISA revealed the 
production of IL-10 from PBMCs after stimulation of PHA-P (4019±315 pg/ml). 
PPCs at first- and second- trimester prohibited the production of IL-10 from 
PHA-P stimulated PBMCs into the MLR cultures (First trimester PPCs: 
2368il44.3, second trimester PPCs: 1748±129.7 pg/ml). 
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Figure 3.25 ELISA of IFN-y in spent media collected from MLR of PHA-P-stimulated 
PBMCs and PPCs. IFN-y (-3000 pg/mL) was detected in the spent media of PBMC 
cultures stimulated by PHA-P. IFN-y was significantly increased in co-cultures ofPPCs of 
second trimester and PHA-P stimulated PBMCs. All data are expressed as means ±SEM 
for four experiments in each group, ***denotes p<0.001 when compared to PBMC alone; 
## denotes p<0.001 when compared to PPCs of first trimester. 
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Figure 3.26 ELISA of IL-10 in spent media collected from MLR of PHA-P 
stimulated-PBMCs and PPCs. IL-10 (-4000 pg/mL) was detected in media of PBMC 
cultures stimulated by PHA-R IL-10 was significantly decreased in co-cultures ofPPCs of 
both groups and PHA-P-stimulated PBMCs. The inhibitory effect of PPCs at second 
trimester was more significant than first trimester. All data are expressed as means ±SEM 
for four experiments in each group, ***denotes p<0.001 when compared to PBMC alone; 
# denotes p<0.05 when compared to PPCs of first trimester. 
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3.5 Xenotransplantation ofICCs into diabetic mouse model 
3.5.1 Blood glucose levels ofdiabetic mice after transplantation 
To investigate the immune response evoked by ICCs in a xenogeneic environment, 
ICCs derived from PPCs of first and second trimester were transplanted into the 
left kidney capsule of 22 STZ-induced diabetic C57/BL6 mice. To determine the 
capacity of ICCs of different trimesters to control hyperglycemia, the blood 
glucose levels of diabetic mice were monitored before and 2 weeks after 
transplantation (Figure 3.27A). Data revealed a drastic drop of blood glucose, in 
both transplanted groups two days after transplantation (First trimester: 
30.74il . l03 mmol/L on day 1 vs 23.84±1.78 mmol/L on day 2; Second trimester: 
29.24±2.43 mmol/L on day 1 vs 26.82i2.32 mmol/L on day 2), compared to sham 
operated diabetic mice. Blood glucose started to rebound on day 3 in mice 
transplanted with second trimester ICCs and persisted at a high level for 2 weeks. 
The blood glucose of mice undergone transplant of PPCs at the first trimester 
remained at a comparable level on day 5. Both first and second trimester ICCs 
failed to normalize blood glucose in this xenotransplantation setting. However, the 
blood glucose levels of mice transplanted with first trimester grafts were 
significantly lower than those having second trimester graft on day 3 (Figure 
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3.27B). Blood glucose levels were slightly lower than that transplanted with 
second trimester grafts since then. 
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Figure 3.27 (A) Blood glucose level of 22 STZ-induced diabetic C57/BL6 mice after 
transplanted with ICCs offirst and second trimester. Blood glucose levels oftransplanted 
mice were monitored for two weeks. Mice transplanted with sterilized PBS were used as 
sham control. * denotes p<0.05 when compared to second trimester. (B) Blood glucose 
level of mice transplanted with first- and second- trimester grafts 3 days after 
transplantation. * denotes p<0.05 when compared to second trimester. 
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3.5.2 Histological evaluation oftransplanted ICCs grafts 
Grafted kidneys were harvested on 2, 4, 7 and 12 days after transplantation for 
histological examination. H-E staining revealed the intact graft under the renal 
capsule on day 2 and 4 post-transplant (Figure 3.28). Successful engraftment was 
evident one week post transplant (Figure 3.29A and B). However, on day 12，allo 
grafts diminished in size significantly (Figure 3.29C and D), suggesting graft 
rejection. 
Immunohistochemical staining demonstrated the mature P_cell marker, PDX-1, in 
the renal capsule of mice undergone ICC transplant for one week, suggesting the 
successful engraftment ofICCs. 
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Figure 3.28 Histology of grafted kidneys harvested from adult STZ-induced C57/^L6 
diabetic mice having undergone transplant. Representative images o f a 13-week-old graft 
are shown. A: H-E staining of the grafts (2 days post transplant) at 10X magnification. B: 
H-E staining o f the graft (4 days ppst transplant) at 10X magnification. G, human fetal 
ICCs graft; K, murine kidney. 
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Figure 3.29 Histology of grafted kidneys were harvested from adult STZ-induced 
C57/BL6 diabetic mice having undergone ICC transplant. Representative image of a 
13-week-old graft are shown. A: H-E staining of the grafts (7 days post transplant) at 10X 
magnification. B: H-E staining of the graft (7 days post transplant) at 40X magnification. 
Human ICC graft was evidnet. C: H-E staining of the graft (12 days post transplant) at 
10X magnification. D: H-E staining of the graft (12 days post transplant) at 40X 
magnification. The size ofICCs graft diminished significantly. G, human fetal ICCs graft; 
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Figure 3.30 Immunohistochemical staining of human PDX-1. Grafted kidneys were 
harvested from adult STZ-induced C57/BL6 diabetic mice having undergone ICC 
transplant on day 7. Representative image of a 13-week-old graft are shown. A: PDX-1 
(reddish brown) was demonstrated under the renal capsule in the grafted kidney at 40X 
magnification. B: Negative control with secondary antibody only. G，human fetal ICCs 
graft; K，murine kidney. 
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3.5.3 Infiltration of CD45 into transplanted ICCs grafts of 1'* and 2"^  trimester 
Leukocytes infiltration to grafted kidney 1 week after transplantation was assessed 
by immunostaining of CD45. Extensive infiltration of mouse CD45+ leukocytes 
was noted in kidney transplanted with second-trimester ICCs (Figure 3.31B and D). 
In contrast, a minimal infiltration occurred in kidney transplanted with 
first-trimester ICCs (Figure 3.31A and C). 
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Figure 3.31 Immunostaining of CD45 in grafted kidneys of adult STZ-induced C57/BL6 
diabetic mice having undergone ICC transplant for one week. Representative images of 
kidney transplanted with first and second trimester ICCs are shown. A-D: CD45 (red 
fluorescence) at 10X magnification (A-B) and 40X magnification (C-D). E-F: DAPI 
staining. Q human fetal ICCs graft; K, murine kidney. 
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TlDM is an autoimmune disease resulting from the autoimmune destruction of 
pancreatic p_cells that leads to the lack of insulin production and failure in glucose 
homeostasis. Transplantation of either whole pancreas or islets is an alternative for 
traditional insulin administration. Among different sources of pancreatic tissues or 
pancreatic islets for transplantation, fetal pancreata have been proven as a promising 
approach for the potential for transplantation of functional p_cells in treating or even 
curing TlDM. This notion is further consolidated by the greater proliferative capacity 
of fetal pancreas (Hayek & Beattie, 1997), compared with adult tissues as well as its 
immune privileged status. Previous studies of the transplantation offetal pancreas into 
diabetic immunoincompetent rodents consistently showed that they proliferate and 
differentiate into mature beta cells after transplantation (Hayek & Beattie, 1997; 
Castaing et al., 2001); more importantly, it also demonstrated successful amelioration 
of hyperglycemic conditions observed in experimental diabetes animals (Castaing et 
al., 2001; Hullett et al, 1987; Tuch et al., 1988; Tuch & Monk, 1991). 
Apart from the functionality of these tissues or cells, another major concern about 
transplantation is the susceptibility to immune rejection. A lower immunogenicity has 
been reported in embryonic tissues when compared to adult tissues (Medawar, 1953). 
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Various fetal tissues, such as fetal kidney (Foglia et al., 1986; Dekel et a l , 1997)，fetal 
intestine (Lopes et al., 2000)，and fetal skin (Erdag et al., 2002) have been consistently 
suggested to be more immune privileged when compared to their adult counterparts. 
Apart from comparison with adult tissues, it was also noted that the immunological 
status o f the fetal tissue itselfindeed correlates with the gestation age of the fetus from 
which the tissues were harvested. Previous studies addressing the immunogenicity of 
fetal kidney (Dekel et al., 2003) demonstrated that first-trimester human fetal kidney 
was less immunogenic than adult and second-trimester ones. Indeed, elder kidney was 
subjected to rejection upon transplantation into humanized mice, while kidney 
obtained from 7 to 8 weeks ofgestation showed no sign of rejection. It was also shown 
that earlier pig embryonic pancreatic tissue harvested on embryonic day 42 (E42) 
exhibited a remarkable reduced immunogenicity in a xenotransplantation model when 
compared to E56 or later embryonic tissues (Eventov-Friedman, 2006). A more recent 
research revealed that human fetal pancreas from first trimester had a significantly 
decreased immunogenicity (Brands et al., 2008); transplantation of these human fetal 
pancreas further revealed a limited cellular infiltration in first-trimester grafts, whereas 
second-trimester grafts were completely infiltrated and rejected. In regard to these 
findings, the immunogenicity of haman fetal PPCs and ICCs from first and second 
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trimester has yet to be elucidated. 
4.1 Expression ofselected immuno-related genes in PPCs and ICCs 
In order to investigate the inherent immunogenic properties of PPCs and ICCs, the 
expression ofseveral selected immune-related genes in PPCs and ICCs were identified 
by RT-PCR in the present study. In this context, immunogenicity of the fetal kidney 
(Dekel et al., 2003) and fetal pancreas (Brands et al., 2008) comparing to their elder 
counterparts have revealed significant changes in expression of a number ofgenes that 
have direct roles in immune response. These genes were categorized into HLA 
molecules, cytokines, chemokines and their receptors, apoptotic related molecules, 
adhesion molecules, molecules of innate immunity and other immunomodulators. 
MHC molecules are among the most potent antigens responsible for allograft rejection 
(Colvin, 1990). In the present study, we demonstrated the mRNA expression of both 
MHC-I and MHC-II at both PPCs and ICCs levels (Figure 3.1). Previous reports have 
shown that undifferentiated hESC (Drukker et al., 2002; Li et al. 2004; Grinnemo et al. 
2006) and human MSCs (Majumdar，2003) express only MHC class I but no MHC 
class II molecules, while expressions of both MHC-I and II molecules were detected 
on human NSCs (Fu et al., 2010). These data showed the differential MHC expression 
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on different types of stem cells and they might contribute to different immunogenicity. 
More importantly, our present data showed that the mRNA expression of MHC-I in 
PPCs is 3-4 folds lower than that of fetal pancreas tissue at the same stage of 
development (Figure 3.2). The lower expression ofMHC-I in PPCs may be partly due 
to the lack of the potentially immunogenic exocrine tissues and other mesenchyme, 
which are digested and removed during the isolation process of PPCs. The finding 
provides some clues that PPCs possess much less immunogenicity than that of fetal 
pancreas, and that it may be a better candidate for the production of insulin-producing 
islet-like cell clusters for clinical transplantation. 
Meanwhile, the expression of several immune related genes, which are closely 
associated with T cell response, including C3, CCL19, TNFSF10 and B7H4 (Figure 
3.1) were also detected in PPCs and ICCs. C3 and CCL19 have been reported to be 
involved in recruiting and stimulating T cells (Ngo et al., 1998; Froster et al., 1999; 
Pratt et al., 2002). Indeed, it was shown that the absence oflocal synthesized C3 in the 
renal grafts could result in remarkable improved graft survival in a murine model, 
implicating the potential role of C3 in modulating acute T-cell mediated rejection 
(Pratt et al., 2002). TNFSF10 has been reported to have co-stimulatory activity with T 
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cells (Chou et al., 2001; Tsai et al., 2004). B7H4, which is the newest member o f the 
B7 family, is a negative regulator of T cell responses (Prasad et al., 2003; Sica et al.， 
2003; Zang et al., 2003). In light of these findings, it is plausible to speculate that 
difference in the expression of these immune related genes contribute directly to the 
differential immunological status oftissues or cells from different gestational ages. 
Similar to MSC O^auta & Fibbe，2007) and hESC (Li et al., 2004; Grinnemo et al., 
2006), the expression of co-stimulatory molecules CD80 and CD86 were not detected 
in PPCs and ICCs. The lacking ofthese co-stimulatory molecules might lead to T cells 
anergy (i.e. fail to respond to their specific antigen) or at least, to some extent, the 
delay in the triggering of immune response by T cells. Of particular interest is the 
focus on the expression o f the non-classical MHC class-I molecules, HLA-G, in both 
PPCs and ICCs. HLA-G molecules have been reported as an immunomodulatory 
molecule that is capable of inhibiting the cytolytic function and proliferation o f N K 
cells and cytotoxic T lymphocytes, as well as the maturation and function of dendritic 
cells (Carosella et al., 2008). HLA-G has also been reported as one of the factors 
associated with the immune modulating properties of MSCs (Rizzo et al., 2008). The 
existence of HLA-G in PPCs and their derivatives ICCs, though of low level, is 
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therefore indicative of the potential immunomodulatory characteristic ofthese cells. 
4.2 Effects of IFN-y and IL-10 on expression of immuno-regulated genes in PPCs and 
ICCs 
The cytokine IFN-y, secreted by thymus-derived cells and NK cells under certain 
conditions of activation, plays a complex and central role in the resistance of 
mammalian hosts to pathogens. IFN- y was originally regarded as an antiviral agent 
(Wheelock EF, 1965) but was later discovered because of its multiple roles in the 
regulation of several aspects of immune response such as stimulation of bactericidal 
activity in phagocytes, orchestration of leukocyte-endothelium interactions and 
stimulation of antigen presentation through class I and class II MHC molecules 
(Boehm et al.，1997). The induction ofMHC expression by IFN-y is important for host 
response to intracellular pathogens since it increases the potential for T cell 
recognition of foreign peptides and therefore promotes the induction of cell-mediated 
immunity. Indeed, the IFN_ y inducible components are not only confined to the MHC 
complex but also to genes responsible for the processing and loading ofpeptides (Kem 
et al., 1995; Boehm et al., 1997; Seliger et al., 2001) IFN-y has been extensively 
reported to induce the expression of MHC molecules in various cell types such as 
MSCs (Chan et al., 2006; Stagg et al., 2006; Chan et al.，2008), NSCs (Odeberg et al., 
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2005), hESCs (Drukker et al. 2002; Li et al. 2004; Grinnemo et al. 2006) and tumor 
cells (Zhao et al.，2007). In this study, it was noted that IFN-y upregulated mRNA 
expression of MHC-I on PPCs in a dose- and time-dependent manner (Figure 3.3). 
Flow cytometry revealed an increase of MHC-I intensity on PPCs after 
IFN-y challenge (Figure 3.4). The current result is in line with previous studies 
indicative of the potential of IFN-y in inducing the capacity antigen presentation in 
PPCs. 
Apart from the potent inductive effect on MHC molecules, we have also examined 
whether IFN-y is capable of inducing other immune related genes, in particular B7H4 
and HLA-G, in PPCs. Previous studies demonstrated a limited capacity of IFN-y in 
inducing B7H4 on freshly isolated human peripheral blood mononuclear cells (T cells, 
B cells, monocytes and DC), where B7H4 is initially absent (Sica et al., 2003). In a 
study ofrenal tubular epithelial cells, the induction ofB7H4 expression needs not only 
IFN-y but also the presence of other proinflammatory factors including TNF-a, IL-10 
and lipopolysaccharide (Chen et al., 2006). In addition, several studies by Kryczek et 
al. have highlighted the role of IL-10, instead of IFN-y, in inducing the expression of 
B7H4 on human overian cancer carcinoma (Kryczek et al., 2006) and APCs (Kryczek 
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et al., 2006). In contrast to the previous studies, dose-dependent increase of B7H4 
expression by IFN-y in PPCs was demonstrated in this study (Figure 3.8). The fmding 
may arouse re-examination of the effect ofIFN-y on B7H4 as well as the possibility of 
IFN-y-induced B7H4 expression to be tissue specific. As a negative regulator o f T cells, 
the induction of B7H4 expression under IFN-y challenge indicates the immune 
privileged status ofPPCs. 
On the other hand, treatment of the macrophages cell lines and monocytes with IFN-y 
increased the mRNA, cell surface and intracellular level of HLA-G in a 
dose-dependent manner (Yang et al., 1996). These convergent results prompt us to 
conclude that the HLA-G is tissue specific, in which trophoblast and activated 
macrophages are able to produce HLA-G, while the HLA-G gene in fibroblast cannot 
be transcribed even stimulated with IFN- y (Yang et al., 1995; Yang et al. 1996). This 
is justifiable by the investigation on the transcriptional regulation of HLA-G genes 
suggestive of the divergence ofregulatory sequences in the promoters ofHLA-G gene, 
when compared with HLA-E and -F, rendering the unresponsiveness to NF-kB, IRF1 
and CIITA mediated induction pathways by IFN- y (Gobin, 2000). In this study, the 
effect of IFN-y on the HLA-G protein expression in PPCs was examined by Western 
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blotting (Figure 3.7). Compared with JEG-3, results revealed that the protein 
translation ofHLA-G was weak in PPCs, while the protein level remained unchanged 
in both JEG-3 and PPCs even stimulated with IFN- y for 2 days. The Westem blot 
analysis appears to be contradictory to that of the mRNA expression (Figure 3.20) in 
which a 2-fold increase were observed in mRNA HLA-G by IFN-y in PPCs of 
first-trimester. As IFN-yregulates MHC-I in a dose- and time-dependent manner 
(Figure 3.3), further investigations need to confirm whether IFN-y treatment at a 
higher dosage and longer period could display any effect on the protein expression of 
HLA-G. On the contrary, the mRNA and protein expression of HLA-G by PPCs were 
induced by IL-10. Several lines ofevidence have suggested the potent role ofIL-10 on 
regulating HLA-G expression, particularly the trophoblast and monocytes (Moreau et 
al.’ 1999). Furthermore, an upregulation of HLA-G by IL-10 is observed in decidual 
stroma cells (Blanco et al., 2008) and cutaneous lymphomas (Urosevic & Dummer, 
2003). More importantly, a recent immunologic study on MSCs proposed that the 
inhibitory effect on T cells and NK cells and the induction of Tregs are mediated 
through the production of soluble HLA-G5 in an IL-10-dependent manner (Selmani et 
al., 2008). In the study, it was revealed that the pre-treatment of a moderate 
concentration ofIL-10 on both PPCs and ICCs resulted in the upregulation in mRNA 
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expression of HLA-G (Figure 3.5 and 3.6). Finally, the protein expression of HLA-G 
in PPCs being congruous to that ofJEG-3, as demonstrated in this study, was noted to 
increase after IL-10 treatment (Figure 3.7). 
Taken together, the exploration of potential upregulation of MHC molecules, B7H4 
and HLA-G levels, by cytokines such as IFN-y and IL-10, in PPCs can be translated 
into in vitro manipulation of the immunological status of PPCs. Thus the elaboration 
of this scenario may help devise a better transplantation protocol by means of 
pharmalogical intervention of cells prior to transplantation. 
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4.3 In vitro studies on immunogenicity ofPPCs and ICCs from 1®* and 2"^  trimester 
4.3.1 Immune-related genes expression 
A study by Rebel et al. reported that, during the development of hematopoietic stem 
cells, the expression of HLA class I and class II molecules would increase from no 
expression at the yolk sac stage to high expression in adult life (Rebel et al., 1996), 
suggesting the development of immunogenic markers during the ontology of cell 
across gestational stage. The present study revealed that a temporal change in the gene 
expression of MHC-I in the progenitor cells increased across 9 to 14 week, where a 
significant expression of MHC-I was observed after 13^ ^ week. Gene expression of 
MHC-II also demonstrated a temporal expression across gestational weeks, with a 
100-fold increase in expression at 12^ ^ week and this level kept plateau since then. 
Comparing to the gene expression level of the two classes ofMHC molecules, MHC-II 
showed a more drastic increase than MHC-I in terms of fold difference. Despite the 
dramatic change in MHC-II gene expression, the level of MHC-II is indeed much 
lower than MHC-I. From this temporal gene expression study, a different pattern of 
increase in these two genes was noted, implying the distinct development progress of 
MHC-I and MHC-II during the ontology of progenitor. 
The differential expression of several genes previously identified in PPCs and ICCs 
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was studied. Similar to PPCs (Figure 3.11A and B), the expression of MHC-I and 
MHC-II in ICCs were found to be increased in second trimester (Figure 3.13A and 
B).Two other pro-inflammatory molecules including TNFSF10 and C3 were 
significantly upregulated in second trimester in both PPCs and ICCs (Figure 3.11 and 
3.13). As both C3 and TNFSF10 participate in the stimulation of T cells, the higher 
expression ofthese genes in second-trimester PPCs and ICCs therefore implies a more 
vigorous T cell stimulation by these cells upon transplantation. On the other hand, the 
gene expression of B7H4 and HLA-G was lower in the second trimester PPCs and 
ICCs. The higher expression of these immune-suppressing genes indicate that the 
immune status in progenitors of first-trimester is more privileged than that of 
second-trimester. These data suggest that the expression of these particular 
immune-suppressing markers, unlike the MHC molecules, may be reduced along the 
gestational development of the fetus. 
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4.3.2 IFN-y activated gene expression 
The immunogenicity of PPCs and ICCs was elucidated by comparing the degree of 
upregulation ofcertain immune-related genes upon IFN-y challenge. It is assumed that 
tissues or cells would be exposed to inflammatory cytokines such as IFN-y (Bradley et 
al., 2002), which could induce MHC molecule expression and antigen presentation to 
accelerate T cell stimulation as a protective mechanism against the foreign grafts 
during transplantation. Herein, results of the study demonstrated an increase in gene 
expression ofMHC-I at both PPC and ICC levels after treatment with IFN-y for 2 days 
(Figure 3.15 and 3.17). Comparing to different trimesters, it was noted that the 
induction in mRNA expression of MHC-I was more intense in second trimester than 
first trimester. The finding was attested by flow cytometry that an increase in surface 
protein expression ofMHC-I from PPCs and ICCs was significantly higher in second 
trimester (Figure 3.16 and 3.18). 
Apart from MHC-I, the effect ofIFN-y on the gene expression ofMHC-II, HLA-G and 
B7H4 in PPCs of first and second trimester were also investigated. It was noted an 
increase of over ten thousand-folds in gene expression of MHC-II in PPCs after IFN-y 
treatments, and a more drastic increase was found in second trimester where the 
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change was 200,000 folds (Figure 3.19). MHC-II has been reported to play a main role 
in transplantation rejection by interaction with CD4+ T helper cells (Archbold et al., 
2008). The drastic upregulation of MHC-II molecules in PPC hence implies the 
susceptibility of PPCs, particularly from second trimester, in being induced 
immunogenic upon IFN-y challenge. 
Besides, although no noticeable change was observed in protein expression of HLA-G 
by IFN-y as discussed in previous section, a slight increase in the mRNA level of 
HLA-G was noted in first-trimester PPCs (Figure 3.20), while concordant to the 
protein level, there was no change in the second-trimester. Furthermore data showed 
an increase in mRNA expression of B7H4 in both trimester but not different 
significantly (Figure 3.21). 
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4.3.3 Mixed lymphocyte reaction 
Upon examination of the difference in the expression of immune related genes, the 
immunological function and the capacity of allogenic recognition and rejection of 
PPCs were studied by MLR. MLR has been extensively employed in many studies to 
determine the immunogenicity of certain type of stem cells. Neural stem cells were 
shown to trigger low but appreciable allogenic lymphocyte proliferation upon 
co-culture (Ubiali et al., 2007). While MSCs have been consistently reported to be 
capable in suppressing allogenic lymphocyte proliferation, irrespective of the site they 
were collected. Demonstration for the immunosuppressive effect was first reported in 
bone marrow derived MSCs from human (Di Nicola et al., 2002; Le Blanc et al., 2003; 
Potian et al., 2003; Tse et al., 2003), baboon (Bartholomew et al., 2002) and murine 
(Djouad et al., 2003; Krampera et al., 2003), showing that MSCs can inhibit T 
lymphocyte activation and proliferation in vitro. Interestingly, previous studies have 
shown that MSC-like cells from other tissues such as adipose tissue (Puissant et al., 
2005) and fetal lung tissue (G6therstr6m et al., 2004) also inhibit lymphocyte 
proliferation and inflammatory cytokine production. Study of Oh et al. revealed the 
suppressive effect of umbilical cord blood-derived MSCs on the allogenic proliferation 
ofresponder lymphocytes (Oh et al, 2008). In the present study, isolated PBMCs were 
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co-cultured with y-irradiated PPCs, and evidence of DNA synthesis of this one-way 
MLR indicated the stimulation ofgrowth of the untreated PBMCs by PPCs. Given that 
cells from fetal pancreas trigger proliferation oflymphocytes in a previous study (Tuch 
et al., 1988), in vitro functional test was employed to analyze the capability of the 
first- and second- trimester PPCs to be recognized by PBMCs, which may lead to 
rejection upon transplantation. Data showed that PPCs triggered the alloreactive 
proliferation of PBMCs in a dose-dependent manner and a low concentration ofPPCs 
(5X102 cell/well) failed to elicit PBMCs proliferation (Figure 3.22). These results are 
therefore supportive of the possibility that PPCs stimulate PBMCs proliferation in an 
intimate manner. While most studies are in agreement that soluble factors are involved, 
as the separation of MSCs and PBMCs by transwell, prevented the inhibition of 
proliferation (Di Nicola et a l , 2002; Tse et al., 2003; Rasmusson et al., 2003). It was 
also suggested that TGF-P and hepatic growth factor (HGF) were mediators of 
suppression of T-cell proliferation (Di Nicola et al., 2002). The possibility that some 
soluble factors may be released from PPCs to trigger the proliferation of PBMCs 
cannot be ruled out. Nevertheless, this notion needs further confirmation by means of 
the MLR in a transwell system using different concentrations ofPPCs. 
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MLR was performed to assess the extent of immunological responses of the PBMCs. 
Strong proliferative responses (>300% compared to control) were observed (Figure 
3.23). Compared to the allogenic control, the stimulation provoked by PPCs is rather 
low, but it was still indicative of the potential to act as non-professional APCs that 
stimulate the immune system. Data show that PPCs from second trimester elicited a 
higher proliferation in PBMCs than that of first trimester. A possible explanation of 
this phenomenon rests on the higher MHC-II expression as previously demonstrated 
since pretreatment of IFN-y in PPCs of both groups showed a significant increase in 
allogenic stimulation in PBMCs, consistent with a remarkable increase in the 
expression of MHC-II molecules in PPCs. It is well recognized that MLR is 
predominantly related to MHC-II (Bach & Amos, 1967). It is therefore indicative of 
the chiefrole ofMHC-II molecules in PPC-induced PBMCs proliferation. In the study, 
a higher proliferation of PBMCs was elicited in the presence of PPCs from second 
trimester, either in basal or IFN-y pretreated conditions, suggesting that progenitor 
cells isolated from fetus oflater gestational ages may probably be more immunogenic. 
These observations are in agreement with the notion that second trimester fetal 
pancreas is more immunogenic than first trimester counterparts, as evidenced 
previously (Brands et al.，2008). In addition, it was noted that stimulated PBMC 
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proliferation by PPCs of first trimester was abolished by pretreatment with IL-10. 
While an increase in IL-10 production in MSC/monocyte culture was reported 
(Aggarwal & Pittenger, 2005; Jiang et al.，2005; Beyth et al., 2005), the neutralization 
of the IL-10 antibody can partially restore T cell proliferation, thus suggesting a 
suppressive role of IL-10 in MLR (Beyth et al.，2005). More recent studies have also 
suggested the involvement of HLA-G in the immunosuppressive effect of MSCs 
Psfasef et al., 2007; Selmani et al., 2008). In view of this fact, the diminished 
PPC-induced PBMC proliferation by IL-10 may be explained by the upregulation of 
HLA-G expression in the cells. 
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4.3.4 Cytokines production of PBMC in MLR 
A significant difference in cytokine production in MLR of 57 renal allograft 
patient/donor pairs was reported (Cartwright et al., 2000). In that study, a strong 
correlation between mitogen-simulated IFN-y secretion and the rejection ofrenal graft 
was proposed. It is therefore plausible to measure the cytokine secretion in MLR in 
order to reflect the in vivo alloreactivity. The analysis ofIFN-y level in the supernatant 
of MLR with PPCs of second trimester and PHA-stimulated PBMCs exhibited a 
significant increase in the production of IFN-y (Figure 3.24). Results appeared to be 
contradictory to those obtained from the MSCs that were shown to reduce IFN-y 
production by PHA-sitmulated PBMCs (Aggarwal & Pittenger, 2005; Oh et al., 2008). 
In the PBMCs, NK cells and CD4+ T cells are classically known as the two main 
sources for IFN-y O^lease refer to section 1.5.1.3).It was verified in co-cultures of 
MSCs with CD4+ cells or NK cells that revealed a significant suppression ofIFN-y in 
the culture supernatant by MSCs (Aggarwal & Pittenger, 2005). Hence the IFN-y 
produced in the MLR was most likely from T cells and NK cells in the PBMCs, which 
were subjected to the regulation ofPPCs. 
On the other hand, the production of the anti-inflammatory cytokine IL-10 by 
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activated DCs and Th2 cells was upregulated in the presence of MSCs (Aggarwal & 
Pittenger, 2005; Jiang et al., 2005; Beyth et al., 2005). In the study PPCs from both 
first and second trimester suppressed IL-10 production in vitro. Despite the 
discrepancy, data suggest the suppression ofIL-10 production by Th2 cells (Ueta et al., 
2002). There were also statistics showing that the renal rejection was in close 
relationship with increased IL-10 production in MLR (Cartwright et al., 2000). In view 
ofthis, it needs to be elucidated whether the production ofIL-10 by DCs and T cells in 
MLR has an implication on a reduced immunogenicity. Results of the study showed 
that first-trimester PPCs might not stimulate the production of pro-inflammatroy 
cytokine IFN-y in co-cultures with PHA-stimulated PBMCs, and hence supported the 
hypothesis that first trimester PPCs possess a lower immunogenicity over second 
trimester PPCs. 
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4.4 In vivo Xenotransplantation ofICCs into diabetic mouse model 
Due to the severe shortage ofadult donor tissue available to transplantation, alternative 
sources of p-cells, such as human or porcine fetal pancreas and insulin-producing 
cells derived from stem cells for transplantation are indispensable. ESC is one of the 
prominent and promising cell sources for the generation of insulin-producing P-cells. 
Previous studies showed that the transplantation ofESC-derived endocrine precursors 
resulted in insulin-positive cells that could rescue STZ-induced hyperglycemia in 
murine model (Soria et al., 2000; Kroon et al., 2008). More recently, the great potential 
of induced pluripotent stem cells (iPS) as an alternative to ESCs has been explored 
because oftheir capacity to give rise to insulin-producing cells (Tateishi et al., 2008). 
Nevertheless, the problem of the formation of teratomas by both ESCs and iPS are yet 
to be solved. The advantage ofusing organ specific progenitor cells depends on their 
lower tumorigenicity and specific differentiation pathways that require minimal in 
vitro manipulations so to obtain fully functional P-cells, compared with those from 
ESCs and iPS. Fetal liver progenitor cells were shown to be induced to differentiate 
into insulin-producing cells and these cells reverse the hyperglycemic conditions in 
immunodeficient mice (Zalzman et al., 2003; Zalzman et al., 2005). In this regard, it is 
amenable to isolate, characterize and culture transplantable ICCs derived from human 
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fetal PPCs (Suen et al., 2008). The PPCs isolated from human fetal pancreas represent 
another promising source of P-cells in treating TlDM. A lower immunogenicity in 
PPCs in vitro and their derived ICCs from first trimester was noted. As the 
immunological status of transplanted ICCs was not yet understood, a pilot study was 
conducted to investigate the in vivo immunogenicity ofICCs. 
It is generally accepted that fetal tissues are less immunogenic than their adult 
counterparts. Renal grafts from adult and second trimester were noted to be completely 
rejected, whereas early kidney precursors showed no signs of rejection (Dekel et al., 
2003). The study ofhuman fetal pancreas demonstrated that tissue from first-trimester 
was less immunogenic than second-trimester grafts; extensive infiltration of 
mononuclear cells were observed when transplanted into humanized mice (Brands et 
al.，2008). Similar results were also found in xenotransplantation of fetal pig pancreas 
into humanized mice that tissues from embryonic day 42 had a remarkably reduced 
immunogenicity in terms of delayed rejection as well as superior glycemia 
normalization (Eventov-Friedman et al., 2006). In the current study, ICCs were 
transplanted into the kidney capsule of STZ-induced diabetic C57BL/6 mice. 
Histological examination of grafted kidney harvested from 2, 4, 7，12 days 
179 
CHAPTER 4 DISCUSSION 
post-transplant revealed a localization of ICCs the cortex of kidney one week 
post-transplant (Figure 3.28). However, the size of observable xenografts was reduced 
drastically on day 12 post-transplant (Figure 3.28), implying that ICC xenografts were 
subjected to immune attack in C57BL/6 mice and rejected thereafter. Although 
xenogeneic islet can trigger both the humoral and cellular immune response of 
recipient, cellular immune response is believed to be more critical in xenograft 
rejection (Gill et al., 1989; Mirenda et al., 1998; Oberholzer et al., 1999). Previous 
findings have shown that mice treated with an anti-CD4 antibody did not reject 
xenogenic skin (Pierson et al., 1989) or islet grafts (Simeonovic et al., 1990). On the 
other hand, the depletion of CD8+T cell did not have any remarkable improvement in 
the survival of these grafts. Accordingly, CD4+T cells were proposed to be the 
predominant cells mediating the xenogenic immune response. Cytokines such as IL-1 
and TNF are known to impair p_cell function in vitro and ultimately lead to cell death 
(Sandler et al., 1990). It was proposed that IL-1 released from the activated 
macrophages would pose an adverse effect on islet grafts which also contributed to the 
destruction o f the xenogenic grafts (Koragren & Jansson, 1994). Immunohistological 
examination has also revealed the expression of mature p-cell marker PDX-1 localized 
on the grafted ICCs (Figure 3.29). Another study also showed the in vivo proliferation 
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and differentiation ofhuman fetal pancreas into mass beta cells after transplanted into 
NOD/scid mice (Castaing et al., 2001). In contrast to these previous findings, the low 
expression ofPDX-1 in the ICCs grafts might reflect the maturation arrest ofthe ICCs 
in vivo. This can be explained by the xenogenic immune responses that reject the 
ICCs. 
In the present study, both ICCs from first and second trimester were not able to 
normalize blood glucose levels in diabetic mice. An initial drop of blood glucose was 
detected 2 days after the surgery, and the blood glucose gradually decreased from day 
3 whereby the blood glucose of first-trimester grafts displayed more drastic decline 
than that ofsecond trimester. A similar glucose profile, i.e drastic glucose levels below 
l lmM on day 1 and day 2 post-transplant followed by a gradual rebound of glucose 
was observed in a study where islets of different species (human, pig, SD rat and 
Lewis rat) were transplanted as xenografts into STZ-induced C57BL/6 mice (Triponez 
et al., 2000). It might account, in part, to the diffusion of graft-secreted insulin into 
surrounding circulation that provides a short-term remedy for hyperglycemia in the 
host. However, the possibility of the surgical procedure that might affect the host's 
blood glucose levels cannot be ruled out. In any case, the mechanism(s) require 
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intensive investigations. On the other 'hand, the failure of ICCs to normalize 
hyperglycemia in diabetic mice can be explained by the incomplete differentiation of 
ICCs into fully mature and functional islets which are able to produce sufficient 
insulin so as to reverse hyperglycemia. Alternatively, the xenogenic environment 
might not render the ICCs to full development in the kidney graft, and not to mention 
the rejection of the graft. Although the current protocol failed to reverse blood glucose 
levels, hyperglycemia in the mice transplanted with both first- and second- trimester 
grafts was sustained since day 5, and generally the blood glucose levels in 
first-trimester grafts were slightly lower than that of second trimester (Figure 3.26). 
These indicate a less extensive xenogenic rejection in ICCs derived from first trimester 
and a limited capacity in lowering blood glucose in the diabetic mice than mice 
transplanted with second trimester ICCs. 
The lymphocyte infiltration into the ICCs grafts were examined by 
immunohistochemistry of Leukocyte common antigen (LCA), which is also called 
CD45. In this study, the amount ofCD45+ cells in the graft area of first-trimester ICCs 
was significantly lower than that in second-trimester grafts (Figure 3.30). Histology 
revealed an extensive infiltration ofCD45+ cells to ICCs in second trimester than that 
offirst trimester, thus a more rapid rejection, consistent with the observation ofhigher 
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blood glucose levels in transplanted mice. The in vivo data are also in line with the in 
vitro results that second trimester was more immunogenic than first trimester in terms 
of basal and cytokine-induced immune-gene expression and a higher potency in 
inducing PBMCs proliferation in MLR. 
183 
CHAPTER 4 DISCUSSION 
4.5 Conclusion 
In conclusion, the current study provides evidence for a reduced immunogenicity of 
human fetal PPCs from first trimester over second trimester. PPCs from first trimester 
express a significantly lower level of pro-inflammatory markers and a higher level of 
immune-suppressing markers than those of second trimester PPCs, even under the 
challenge ofIFN-y. First-trimester PPCs also possess a reduced alloreactivilty in MLR 
with PBMCs, as indicated by a reduced PBMCs proliferation and pro-inflammatory 
cytokine production. Transplantation ofPPC-derived ICCs from first trimester showed 
a remarkably reduced cellular infiltration than that of second-trimester grafts. Taken 
together, human fetal PPCs from first trimester might be immunologically superior for 
islet transplantation in treating TlDM. 
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4.6 Further studies 
While the present study has been focusing on the immunogenicity of human fetal 
PPCs, the immunological properties of ICCs would require complete illustration. 
Questions remain on whether there would be any alternation in the immunogenic 
makeup ofICCs, disregarding oftheir gestation age, during the differentiation process 
from PPCs. A more realistic animal model, such as humanized NOD/scid mice, should 
be employed for transplant in order to elucidate the alloreactivity in ICCs of different 
stage of maturation. Focus would also be on in-depth investigation on the potential 
immunomodulatory effect ofIFN-y and IL-10 on PPCs and ICCs for in vitro or in vivo 
therapeutic manipulation of the immunogenicity ofthese cells. 
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